Oligoaminoamide-Based siRNA Formulations for Folate Receptor-Directed Tumor Targeting and Gene Silencing

Dian-Jang Lee

aus

Taipeh, Taiwan

2016
Erklärung


Eidesstattliche Versicherung

Diese Dissertation wurde eigenständig und ohne unerlaubte Hilfe erarbeitet.

München, 03.11.2016

....................................................

Dian-Jang Lee

Dissertation eingereicht am 03.11.2016

1. Gutachter: Prof. Dr. Ernst Wagner
2. Gutachter: Prof. Dr. Gerhard Winter

Meiner Familie
“Wir müssen lernen, magische Kugeln zu gießen, die gleichsam wie Zauberkugeln des Freischützen nur
die Krankheitserreger treffen.”
(We have to learn how to cast magic bullets, which behave like the magic bullets of a marksman and
exclusively hit pathogens).

Paul Ehrlich
Nobel Prize in Physiology or Medicine, 1908
# Table of Contents

1 Introduction ..................................................................................................... 1

1.1 RNAi machinery ............................................................................................ 1
1.2 Antitumoral siRNA therapeutics ................................................................. 2
1.3 Sequence-defined oligomers for siRNA delivery ........................................... 3

1.3.1 Oligoglutamyl-methotrexate (MTX) as bifunctional targeting ligand .......... 5
1.3.2 Combinatorial optimization of oligomers by covalent coupling ................. 7
1.3.3 siRNA lipopolyplexes .............................................................................. 8

1.4 Aim of the thesis ............................................................................................ 9

2 Materials and Methods ................................................................................ 11

2.1 Materials ....................................................................................................... 11

2.1.1 Chemicals and reagents ........................................................................... 11
2.1.2 siRNA duplexes ...................................................................................... 11
2.1.3 Oligomers ................................................................................................ 12

2.2 Methods ......................................................................................................... 13

2.2.1 siRNA polyplex formation ...................................................................... 13
2.2.2 Formulation of targeted combinatorial polyplexes (TCPs) ......................... 13
2.2.3 Formulation of targeted lipopolyplexes (TLPs) ........................................... 14
2.2.4 Fluorescence correlation spectroscopy (FCS) .......................................... 15
2.2.5 Size and zeta potential by dynamic light scattering (DLS) measurements ... 16
2.2.6 Gel shift assay .......................................................................................... 16
2.2.7 Particle imaging by transmission electron microscopy (TEM) ................. 16
2.2.8 Atomic force microscopy (AFM) ............................................................... 16
2.2.9 Cell culture ............................................................................................... 17
2.2.10 Cellular association and internalization study .......................................... 17
2.2.11 Ligand competition study ....................................................................... 18
2.2.12 Fluorescence resonance energy transfer (FRET) intensity in Cy5/TAMRA double-labeled siRNA ................................................................. 18
2.2.13 Flow cytometry ....................................................................................... 18
2.2.14 Intracellular distribution of siRNA polyplexes by time-lapse imaging ........ 19
2.2.15 Endosomal escape of siRNA polyplexes by 3D image reconstruction .... 19
2.2.16 Colocalization analysis of siRNA polyplexes and endolysosomal vesicles ... 20
2.2.17 Fluorescence resonance energy transfer (FRET) imaging in Cy5/TAMRA double-labeled siRNA ...................................................................................... 20
2.2.18 Pre-embedding immuno-labeling for TEM .............................................. 21
2.2.19 Gene silencing mediated by GFP-siRNA in vitro .................................... 21
2.2.20 Cytotoxicity mediated by EG5 knockdown or MTX conjugates .............. 22
2.2.21 Evaluation of mitotic aster formation ...................................................... 22
2.2.22 Quantitative real-time polymerase chain reaction (qRT-PCR) .................. 22
# Table of Contents

2.2.23 Tumor mouse model................................................................. 23  
2.2.24 Biodistribution study ............................................................... 23  
2.2.25 Antitumoral potency mediated by EG5 knockdown and MTX conjugates .......... 24  
2.2.26 Gene silencing mediated by EG5-siRNA *in vivo* .................................. 24  
2.2.27 Blood biochemistry examinations ............................................. 24  
2.2.28 Statistical analysis ........................................................................ 24  

3 Results ............................................................................................................ 25  
3.1 Glutamylated MTX-conjugated nanoplexes ........................................ 25  
   3.1.1 Oligomer structures ........................................................................ 25  
   3.1.2 Physicochemical characteristics of MTX-conjugated siRNA polyplexes .... 27  
   3.1.3 MTX as targeting ligand for receptor-mediated uptake ......................... 31  
   3.1.4 Gene silencing efficiency ............................................................... 33  
   3.1.5 Augmented cytotoxicity by MTX conjugates and EG5 gene knockdown .... 36  
   3.1.6 Prolonged intratumoral retention .................................................... 38  
   3.1.7 Dual *in vivo* therapeutic effects by MTX-conjugated siRNA polyplexes .... 39  

3.2 Targeted combinatorial polyplexes (TCPs) ............................................ 43  
   3.2.1 Formation of TCPs ........................................................................ 43  
   3.2.2 Physicochemical characterizations .................................................. 46  
   3.2.3 Receptor-mediated uptake of TCPs ................................................. 48  
   3.2.4 Gene silencing efficiency of TCPs .................................................. 50  
   3.2.5 Tumor-specific toxicity mediated by EG5 gene silencing ..................... 51  
   3.2.6 Distribution of TCP in tumor-bearing mice upon systemic administration .... 52  
   3.2.7 Tumor-targeted EG5 gene silencing *in vivo* ..................................... 53  

3.3 Targeted lipopolyplexes (TLPs) ............................................................. 55  
   3.3.1 Formation of TLPs ........................................................................ 55  
   3.3.2 Receptor-mediated internalization and intracellular distribution of TLPs .... 60  
   3.3.3 siRNA release and reporter gene silencing by TLPs ............................ 64  
   3.3.4 Receptor-dependent antitumoral activity by EG5 gene silencing ............. 67  
   3.3.5 siRNA release kinetics and stability in cells ...................................... 69  
   3.3.6 Tumoral delivery and gene silencing upon systemic administration ....... 72  

4 Discussion ........................................................................................................ 77  
4.1 Oligoglutamyl-MTX-conjugated nanoplexes ........................................ 77  
4.2 Targeted combinatorial polyplexes (TCPs) ............................................ 81  
4.3 Targeted lipopolyplexes (TLPs) ............................................................. 83  

5 Summary ........................................................................................................... 85  
6 Abbreviations ................................................................................................. 87  
7 References ......................................................................................................... 89
8 Publications ...............................................................................................................96

8.1 Original articles .................................................................................................96
8.2 Book chapter .......................................................................................................96
8.3 Submitted manuscript .........................................................................................96
8.4 Oral presentations ...............................................................................................96
8.5 Poster presentations ...........................................................................................97
8.6 Honors ................................................................................................................97

9 Acknowledgements ..................................................................................................98
Introduction

Since the discovery of RNA interference (RNAi), small interfering RNA (siRNA) provides a promising option for drug development in oncology over the past decade [1]. RNAi is an evolutionarily conserved phenomenon for sequence-specific gene silencing among multicellular organisms as diverse as plants, worms, yeast and humans, in which double-stranded RNA triggers specific degradation of the complementary mRNA sequence to silence the expression of target gene [2]. Since it was found that siRNA can also invoke RNAi responses in mammalian cells [3], this novel strategy has rapidly become a powerful tool for sequence-specific gene silencing, with many lead compounds in various stages of clinical development [4]. As viral vectors are not compatible with the delivery of synthetic siRNA, different non-viral delivery systems have sparked intense investigations [5].

1.1 RNAi machinery

In mammalian cells, siRNA sequences are produced by the ribonuclease Dicer [6]. Dicer, an endonuclease of the RNase III family, precisely produces RNA duplexes ~21-23 nucleotides in length with a dinucleotide overhang at 3’ end and a monophosphate group at 5’ end [7]. The siRNA duplex length and characteristic termini are required for efficient recognition by and integration into the RNA-Induced Silencing Complex (RISC) [8]. RNAi is processed when siRNA is loaded into RISC [8], where the strands are separated, and the antisense strand (guide strand) directs sequence-specific cleavage of target mRNA in a manner of Watson-Crick base pairing [9]. The core of the RISC complex and crucial processor of RNAi is the Argonaute protein. There are four human Argonaute proteins (AGO 1-4), and siRNA-induced gene silencing is mediated via AGO2 [10]. AGO2 attaches the guide siRNA strand, extrudes the passenger strand, and then repeats target mRNA recognition, cleavage, and release [7]. Structurally, AGO2 has three functional domains: PAZ, MID, and PIWI. PIWI docking an RNase H fold is the motor for RISC’s slice activity [11]. For RISC loading, PAZ domain is able to specifically recognize the 3’ dinucleotide of siRNA, and such overhang enters deep into a hydrophobic pocket of the domain [12]. At the same time, the 5’ phosphate group inserts between the MID and PIWI domains, binding to a magnesium ion [13]. For guide-strand selection, both the absolute and relative stabilities of the base pairs at the 5’ end of the two siRNA strands determine which strand participates in the RNAi pathway, herein Argonaute selects the one with the less thermodynamically stable 5’ end as the guide strand and cleaves the other one. Moreover, the guide siRNA strand inside RISC can be repeatedly used to target other complementary mRNA sequences. Such remarkable properties
have rendered the synthetic siRNA molecules for the therapeutic knockdown of endogenous mRNA [14].

1.2 Antitumoral siRNA therapeutics

Recently, numerous novel RNAi targets for malignancies have been identified, such as for breast cancer (WEE1) [15], glioma (PFKFB4) [16], multiple myeloma (GSK3) [17], and pancreatic cancer (CHK1) [18]. By silencing important oncogene targets in cancer cells, the siRNA therapeutics are showing impressive potential with several clinical trials are underway [19]. These include TKM-080301, siG12D LODER, siRNA–EphA2–DOPC, DCR-MYC, ALN–VSP02 and Atu027 (Table 1.2.1), providing hope to those with limited options for cancer survival. For examples, the company Arbutus developed TKM-PLK1 for hepatocellular carcinoma (HCC), using LNPs to deliver siRNA against polo-like kinase (PLK) [20]. PLK is mostly overexpressed in malignant cells, and inhibition of PLK results in reduced cell division [21]. Phase I trials indicated a dose-dependent effect and 19.3% reduction in tumor size [22]. Moreover, KRAS gene is overexpressed in more than 90% of pancreatic ductal adenocarcinomas [22]. To downregulate the KRAS gene, the company Silenseed’s siG12D LODER is composed of polylactic glycolic acid as polymer matrix and an unmodified siRNA against a mutant KRAS gene, KRAS-G12D [22]. Phase I trials that combined siG12D LODER with chemotherapy resulted in a median survival of 16 months, compared with a median survival of 10–13 months for patients treated with only chemotherapy. More encouragingly, two patients have survived beyond 2 years [22]. siG12D LODER has now initiated Phase II/III trials of repeated doses every 4 months combined with chemotherapy [20]. As another example, EphA2 gene encoding the epithelial cell receptor protein–tyrosine kinase is frequently overexpressed in cancer cells and its expression level is related to tumor aggressiveness, tumor recurrence and survival [23]. In MD Anderson Cancer Center, Phase I study in 40 advanced solid tumors with a liposome-based siRNA therapeutic, siRNA-EphA2-DOPC, is currently ongoing to determine the maximum tolerated dose and efficacy of EphA2 gene silencing [20]. In addition, the company Dicerna has launched Phase II trials with DCR-MYC, a Dicer substrate–based RNAi therapeutic targeting the MYC oncogene in solid tumors (especially HCC), multiple myeloma and lymphoma [20].

One implicated oncological target gene is eglin 5 (EG5, also known as Kif11, KSP), a member of the Kinesin-5 subclass of kinesins, which is involved in the assembly and organization of the mitotic spindle apparatus, and is responsible for centrosome separation in cell division [24]. Thus, targeting siRNA against EG5 (siEG5) that corresponds to a sequence of the EG5 coding region
Introduction

conserved between human and mouse, would represent an excellent strategy to hinder mitosis, leading to G2 arrest and eventually cell death of cancer cells [25-27]. However, early in vivo studies with siRNA described nuclease sensitivity and undesirable immunostimulatory effects [28]. For this, Judge et al. used 2' OMe-modified siRNA to prevent the recognition by the innate immune system [29, 30].

Table 1.2.1. RNAi-based drugs in clinical trials.a

<table>
<thead>
<tr>
<th>Drug</th>
<th>Target</th>
<th>Delivery system</th>
<th>Disease</th>
<th>Phase</th>
<th>Company</th>
<th>NCT No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>TKM-080301 PLK1</td>
<td>LNP</td>
<td>HCC</td>
<td>I/II</td>
<td>Arbutus</td>
<td>NCT01262235</td>
<td></td>
</tr>
</tbody>
</table>
| siG12D LODER     | KRAS-G12D    | Polymer (local administration) | Pancreatic cancer                     | I     | Silenseed  | NCT01188785  \\
|                  | EphA2        | LNP             | Advanced cancers                       | I     | MD Anderson | NCT01591356  \\
| siRNA–EphA2–DOPC | EphA2        | LNP             | Solid tumors, Multiple myeloma, Lymphoma | I     | Dicerna    | NCT02110563  \\
|                  | MYC          | LNP             | Solid tumors, Multiple myeloma, Lymphoma | I/II  | NCT02314052 |
| ALN–VSP02        | KSP & VEGF   | LNP             | Solid tumors                           | I     | Alnylam    | NCT01158079  |
| Atu027           | PKN3         | LNP             | Pancreatic cancer                      | II    | Silence Therapeutics | NCT01808638 |

aAbbreviations: LNP, lipid nanoparticle; HCC, hepatocellular carcinoma; PLK1, polo-like kinase 1; LODER, local drug eluter; DOPC, 1,2-dioleoyl-sn-glycero-3-phosphocholine; EphA2, ephrin type-A receptor 2; KRAS-G12D, Kirsten rat sarcoma viral oncogene homolog G12D mutation. The information for clinical trials are published by U.S. National Institutes of Health [20].

1.3 Sequence-defined oligomers for siRNA delivery

The main hurdles against efficient cytosolic siRNA delivery include: (i) high charge distribution and size of siRNA impede its translocation through the cell membrane [31]; (ii) siRNA is biologically fragile and is actively targeted by nucleases for degradation in extracellular and intracellular environments [32]; (iii) upon systemic administration, negative charge of siRNA may be recognized by pattern recognition receptors (PRRs) triggering the innate immune response [5]; and naked siRNA is subject to rapid elimination by renal clearance [33]. It is generally realized that transforming siRNA from valuable research tool to clinical application is highly dependent on the development of safe and efficient delivery systems.

siRNA carriers have recently shown great potential for low toxicity and effective delivery to target cells/tissues [31, 34]. Recently, our laboratory, has developed a solid phase supported synthesis method [35], where oligoamidoamine building blocks (as proton sponge motifs) were applied together with lysines (as branching units), various fatty acids (as stabilizing hydrophobic domains), and cysteines (as bioreversible disulfide-forming units) to generate sequence-defined monodisperse peptide-like oligomers [26, 36, 37].
It is widely recognized that different non-viral vectors utilize different endocytic pathways in order to gain access to the cells [38]. Consequently, both vectors and their respective cargo remain to high extent entrapped in endosomal compartments and this endosomal entrapment serves as the main limiting factors in their efficient delivery. Many different strategies have been investigated aiming to induce endosomal escape [39]. Above-mentioned oligoamidoamine-based building blocks such as succinoyl-tetraethylene pentamine (Stp) and succinoyl-pentaethylene hexamine (Sph) [40] are designed in the way that they would act as proton sponge motifs, which express about 20% protonation of nitrogens at neutral pH and would become increasingly protonated with endolysosomal acidification. The influx of protons is followed by subsequent rupture of the endosomal membrane and release of the polyplexes [36, 39].

It is believed that polyplex formation between the cationic carriers and nucleic acids, i.e. siRNA, takes place due to the electrostatic interaction between the nitrogens of the oligomers and the phosphates of the siRNA [41]. In addition to electrostatic interaction, hydrogen bonding and hydrophobic interactions can increase polyplexes stability [39]. For example, lipid moieties can be incorporated to increase hydrophobicity, improve polyplex stability and also introduce pH-dependent lytic activity, leading to enhanced membrane destabilization with endosomal acidification [35, 36]. Moreover, the introduction of cysteines that allows disulfide crosslinking has been shown to increase particle stability during polyplex formation [36, 42]. In this case, it has been hypothesized that siRNA might help bringing the positively charged oligomer molecules together into close distance by charge neutralization, followed by disulfide formation to fix the nanostructure. Disulfide bonds are stable in the bloodstream but cleaved in the reducing environment of the cytosol [39], facilitating dissociation of the particle and release of the siRNA. Furthermore, these oligomers could be synthesized with very diverse molecular topologies such as i-shape, T-shape, U-shape or branched configurations. Promising candidates of the library such as oligomers 49, 229, 278, 386 and 454 (Figure 1.3.1) have shown high activity for siRNA delivery, enabling successful silencing of target genes of interest in both in vitro and in vivo settings [35-37]. The addition of tyrosines to the terminal cysteines of 454 has rendered the carrier even more potent in terms of gene silencing efficiency [37]. From in vivo perspective, the three-arm oligomer 386 has displayed the fastest onset of protein knockdown and highest in vivo antitumoral effect [26]. These oligoamidoamine-based oligomers are also flexible for further functional modifications, as targeting and shielding moieties have been successfully incorporated into such oligomers [33].
Introduction

Figure 1.3.1. The structures of oligomers 49, 229, 278, 386 and 454. Apart from 386, these oligomers are modified with lipid moieties and contain terminal cysteines, which form intermolecular disulfide bonds after siRNA polyplex formation. The oligotyrosines are added to the terminal cysteines of oligomer 454 as stabilizing components for siRNA polyplex formation.

1.3.1 Oligoglutamyl-methotrexate (MTX) as bifunctional targeting ligand

To improve the tissue selectivity and cellular uptake, i.e. to achieve targeted delivery, cationic oligomers could be modified with targeting motifs such as antibodies, antibody fragments, small molecules, and peptides [33, 43]. As previously reported, oligomer 356 (Figure 1.3.2) contains a electrostatic nucleic acid binding core consisted of a branched two-arm structure comprising eight Stp units providing the positive charge for siRNA binding, and two cysteines for disulfide-based polyplex stabilization [33]. Polyethylene glycol (PEG) comprising 24 ethylene oxide units are positioned in the center of the cationic two-arm cores for shielding of the positive surface charge and preventing unspecific protein bindings. Moreover, the folate is attached to the exposed part of the PEG segment, as targeting ligand for FR-overexpressing tumors. As a result, this folate-conjugated PEGylated oligomer can formulate siRNA as neutrally-charged monomolecular nanoplexes with hydrodynamic diameter of ~6 nm, successfully exhibiting FR-specific cellular uptake and gene silencing \textit{in vitro} and \textit{in vivo}. 
An interesting strategy is to use a ligand that would be multifunctional, for example combining targeting capacity with chemotherapeutic activity. One molecule that could act in this manner is the widely used antifolate drug, methotrexate (MTX). MTX and folate (Figure 1.3.3) enter cells via two major transport systems: folate receptors (FR) and reduced folate carrier (RFC) [44]. The folate receptors consist of several isoforms. FR-α alone is expressed in normal epithelial cells and is frequently overexpressed in numerous carcinomas [45]; while RFC is ubiquitously distributed [46]. A broad variety of FR-targeted experimental therapies have focused on FR-α, which has thus served as a golden standard for targeted drug delivery [47]. Mostly, transport of low molecular weight (LMW) MTX occurs via the RFC (K_m~1–5 μM); however, LMW MTX also binds to the FR-α in the cells with FR-α upregulation [48]. After entering cells, glutamic acid residues are attached to MTX by the folylpolyglutamyl synthetase (FPGS), producing MTX polyglutamates which are retained in the cytosol and represent the more pharmacologically active form [49]. Polyglutamylated MTX inhibits dihydrofolate reductase (DHFR), resulting in inhibition of de novo thymidylate and purine synthesis, and consequently DNA and RNA synthesis [46]. Previous studies from our lab involving modification of polyglutamylation in covalent MTX-PEG-STP conjugates (638-641, see Figure 1.3.4) gave critical evidence that the glutamylation degree is closely related to DHFR inhibition potency, cytotoxicity, and cellular uptake [50]. In that work, a library of targeted PEGylated oligomers with bifunctional MTX ligands, in order to mediate FR-specific cellular delivery and augmented tumor suppression was designed and synthesized.
1.3.2 **Combinatorial optimization of oligomers by covalent coupling**

Successful applications of RNAi-based cancer therapy require sufficient intracellular delivery of siRNA to the site of action and effective knockdown of targeted transcripts. Thus, an ideal siRNA delivery system should possess multifunctionalities to conquer multiple barriers all the way to its target site [31]. Generally, the siRNA carrier needs to incorporate siRNA into nanoparticles of suitable size to protect siRNA from nucleases and renal clearance, and also enables passive targeting to tumor by enhanced permeability and retention (EPR) effect [51].

Combination of two different oligomers by covalent coupling provides an efficient alternative to obtain a multifunctional carrier, which may formulate therapeutic nucleic acids and overcome possible disadvantages of single oligomers. For example, a c-Met targeting PEGylated oligomer, which is deficient in DNA condensation, was combined in a 7/3 ratio with a 3-arm oligomer to facilitate nucleic acid compaction, and such compaction was critically required for efficient intravenous gene delivery, and resulted in greatly enhanced ligand-dependent gene expression in the distant tumor [52].
1.3.3 siRNA lipopolyplexes

As explained above, oligomer 356 (Figure 1.3.2.)成功地展示了FR-specific cellular uptake and gene silencing in vitro and in vivo [33]. However, some limitations remained to be overcome. First, because of small particle size, 356 siRNA nanoplexes displayed a short circulation time of 15 min followed by renal excretion after systemic administration. Second, since 356 siRNA nanoplexes lack robust endosomal escape capacity, modification of siRNA with an endosomolytic Inf7 peptide is necessary for potent gene suppression [33, 53]. For systemic siRNA administration, an established strategy is to formulate various combinations of lipids and polycations to generate lipopolyplexes [54-56]. Hitherto, sorts of cationic polymers were utilized in lipopolyplexes such as branched polyethylenimine (bPEI), linear polyethylenimine (IPEI), poly-L-lysine (PLL), poly (beta-amino ester), protamine, chitosan, polyallylamine (PAA) and other constructs [57-59]. Low molecular weight polyethylenimine (PEI F25-LMW) and various lipid combinations are formulated as optimized lipopolyplexes for siRNA delivery [55]. Addition of negatively charged and rigid liposomes to pre-condensed polyplexes decreased intrinsic cytotoxicity of PEI [55]. Moreover, combination of PEI (2 kDa) and various cationic liposomes with or without transferrin was developed by Penacho et al. [60]. Among these transferrin-modified formulations lipopolyplexes composed of DOTAP/Chol showed the upmost transfection efficiency [60]. These results showed that the combination of the polyplexes with fatty acids renders DNA/siRNA carriers desirable physicochemical and pharmacological characteristics for a more efficient cargo delivery.
### 1.4 Aim of the thesis

Potent sequence-selective gene silencing by siRNA therapeutics is promising in cancer treatment, and the goal of this thesis was to optimize nanosized siRNA delivery system for *in vivo* application evaluated using antitumoral siRNA in the FR-overexpressing tumor models. Through various experiments we expected to achieve the following aims:

(i) The first aim was to evaluate a library of PEGylated Stp oligomers with bifunctional MTX ligands for siRNA delivery. It had to be investigated whether these siRNA polyplexes can access tumor cells specifically through the FR, and to be evaluated if Inf7-modified siEG5 (siEG5-Inf7) can be formulated with MTX-linked oligomers to mediate tumor cell-specific cytotoxicity *in vitro*. It also had to be examined if the transfection efficiency was elevated with an increasing degree of polyglutamylation of MTX-conjugated oligomers. Eventually, intratumoral treatment in KB tumor-bearing mice had to be performed, in order to find out whether these siRNA polyplexes can prolong tumoral retention time and enhance antitumoral effect *via* dual mechanisms.

(ii) Since systemic delivery of siRNA directed to the tumor site remains a major limitation, this thesis (together with the thesis of my colleague Dr. Dongsheng He) also aimed to optimize the physicochemical properties of polyplexes by combinatorial optimization of PEGylated folate-conjugated oligomer and 3-arm oligomer to generate targeted combinatorial polyplexes (TCPs). For uni-directional fast coupling between the two groups of oligomers, the cysteine thiol groups of one of the oligomers ought to be activated with 5,5’-dithio-bis(2-nitrobenzoic acid) to achieve a fast chemical linkage through disulfide formation with the free thiol groups of the other oligomer. The particle size, surface charge and siRNA binding activity of TCPs had to be assessed. By immuno-TEM in collaboration with Prof. Margus Pooga’s lab (Institute of Molecular and Cell Biology, University of Tartu), we sought to confirm the involvement of FR in the cellular uptake of TCPs, and to gain more detailed insight into how these polyplexes associate with receptors and how they are endocytosed by cells. Finally, by *i.v.* administration of such formulation in L1210 tumor-bearing mice, we had to examine if siEG5-Inf7 TCPs were able to induce siRNA delivery and subsequent gene silencing in the tumors.

(iii) Next, siRNA polyplexes had to be optimized by co-formulating with a PEGylated folate-conjugated oligoaminoamide and one of several lipo-oligoaminoamides to develop targeted lipopolyplexes (TLPs), in which terminal cysteines of carriers stabilized TLPs by disulfide cross-linkage. This strategy was applied to render TLPs tunable sizes, surface shielding and improved...
siRNA binding. In collaboration with Prof. Kazunori Kataoka's lab (Innovation Center of NanoMedicine and University of Tokyo), time-lapse confocal microscopy was used to investigate the colocalization of TLPs with endosomes and lysosomes and the onset of siRNA release from late endosomes. In addition, double-labeled siRNA had to be applied to analyze intracellular stability by FRET analysis. As to be tested by systemic administration in L1210 tumor-bearing mice, TLPs were anticipated to improve pharmacokinetic profile and mediate tumoral gene silencing efficiency with siEG5.
2  Materials and Methods

2.1  Materials

2.1.1  Chemicals and reagents

Inf7 peptide (GLFEAIEGFIENGWEGMIDGWYGC-amide) was obtained from Biosyntan (Berlin, Germany). 2-Chlorotrityl chloride resin, all Fmoc or Boc protected \( \alpha \)-amino acids, peptide grade dimethylformamide (DMF), \( N \)-methyl-2-pyrrolidone (NMP), \( N,N \)-diisopropylethylamine (DIPEA), piperidine and trifluoroacetic acid (TFA) were purchased from Iris Biotech (Marktredwitz, Germany). Benzotriazol-1-yl-oxy-tris-pyrrolidino-phosphonium hexafluorophosphate (PyBOP) and syringe microreactors were obtained from Multisyntech GmbH (Witten, Germany). Folate, methotrexate, 1-hydroxy-benzotriazole (HOBt), triisopropylsilane (TIS), tris(2-carboxyethyl)phosphine (TCEP), 5,5'-dithio-bis(2-nitrobenzoic acid) (DTNB), 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU), 3,6-dioxo-1,8-octanedithiol (DODT), dimethylsulfoxide (DMSO) and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) were purchased from Sigma-Aldrich (Munich, Germany); hydrazine hydrate solution from Merck (Darmstadt, Germany), and 25% ammonia solution from Carl Roth (Karlsruhe, Germany). N\(^{10}\)-(trifluoroacetyl) pteroic acid was obtained from Niels Clauson-Kaas A/S (Farum, Denmark), and Fmoc-N-amido-dPEG\(_{24}\)-acid from Quanta Biodesign (Plain City, OH, USA). Fetal bovine serum (FBS) was purchased from Invitrogen (Karlsruhe, Germany), glucose from Merck (Darmstadt, Germany), and HEPES from Biomol GmbH (Hamburg, Germany). All other solvents were purchased from Sigma-Aldrich (Steinheim, Germany), Iris Biotech (Marktredwitz, Germany), Merck (Darmstadt, Germany), Bernd Kraft (Duisburg, Germany) or AppliChem (Darmstadt, Germany).

2.1.2  siRNA duplexes

For flow cytometry, Cy5-labeled siAHA1 was used:

- sense: 5'-(Cy5)(NHC\(_6\))-GGAuGAAGuGGAGAuAGudTsdT-3';
- antisense: 5'-ACuAAUCUCcACUUCaUCCdTsdT-3'

(Axolabs GmbH, Kulmbach, Germany).

For immuno-TEM, biotinylated siRNA was used:

- sense: 5'-(biotinP)GAAACUCcGUUUUGUGUAdTdT-3';
- antisense: 5'-UACACAAAUCAGCGAUUUCCdTdT-3' (P: phosphodiester) (Axolabs GmbH, Kulmbach, Germany).
Materials and Methods

For CLSM, Alexa Fluor (AF) 647-labeled siRNA was applied:
sense: 5'-AF 647-NH₂C₆-CUUCAGCGUACUCGAdTdT-3'; antisense: 5'-UCGAAGUACUCAGCGUACUCGAdTdT-3' (Gene Design, Ibaraki, Japan).

For gene silencing studies, siRNA sequences were modified with Inf7 peptide: siGFP-Inf7 (sense: Inf7-ss-C₆-5'-AuAucAuGGccGCuACuAACuDdTsdT-3'; antisense: 5'-UGCUUGUCCGcAUGAuAUCdTsdT-3') and control sequence siCtrl-Inf7 (sense: Inf7-ss-C₆-5'-AuAucAuGGccGUuAuUGdTsdT-3'; antisense: 5'-CuAAuAcAGGCcAAuAcAUdTsdT-3'). Unmodified siRNA sequences were exploited as comparison: siGFP (sense: 5'-AuAucAuGGccGCuACuAACuDdTsdT-3'; antisense: 5'-UGCUUGUCCGcAUGAuAUCdTsdT-3') and siCtrl (sense: 5'-AuAucAuGGccGUuAuUGdTsdT-3'; antisense: 5'-CuAAuAcAGGCcAAuAcAU dTsdT-3'); (Axolabs GmbH, Kulmbach, Germany).

For FRET study, Cy5/TAMRA double labeled siRNA was used (sense: 5'-Cy5-NH₂C₆-CUUCGCUUGAGUACUCGAdTdT-3'; antisense: 5'-UCGAAGUACUCGAdTdT-3'); (Hokkaido System Science, Sapporo, Japan).

To evaluate in vivo biodistribution, we used Cy7-labeled siAHA1 (sense: C₆-ss-C₆-5'-GGAuGAAGuGGAGAuuAGudTsdT-3'; antisense: 5'-(Cy7)(NH₂C₆)ACuAACUCcAcAUccAUCCdTsdT-3'); (Axolabs GmbH, Kulmbach, Germany).

small letters: 2'-methoxy-RNA; s: phosphorothioate

2.1.3 Oligomers

Oligomers A-PEG24-K(Stp4-C)₂ (188), K(PEG24-MTX)-K(Stp4-C)₂ (638), K(PEG24-E₂-MTX)-K(Stp4-C)₂ (639), K(dPEG24-E₁-MTX)-K(Stp4-C)₂ (640), K(PEG24-E₆-MTX)-K(Stp4-C)₂ (641) and K(PEG24-αMTX)-K(Stp4-C)₂ (642) were provided by Dr. Ulrich Lächelt [50, 53], C-Stp₄-K(Stp4-C)₂-dPEG₂₄-Folate (356) was provided by Dr. Dongsheng He and Philipp Klein [33], C-Stp₃-K-(Stp₃-C)₂ (386), C-H-(Stp-H)₃-K-[(H-Stp)₃-H-C]₂ (689), K-(PEG₂₄-Folate)-K-[K-(Sph₄-C)]₂ (709), K-(PEG₂₄-Folate)-K-(Sph₄-Y₃-C)₂ (717), TNB-C-Stp₃-K-(Stp₃-C-TNB)₂ (769), TNB-C-H-(Stp-H)₃-K-[(H-Stp)₃-H-C-TNB]₂ (770), K-(PEG₂₄-Folate)-K-[K-(Sph₄-C-TNB)]₂ (873) and K-(PEG₂₄-Folate)-K-(Sph₄-Y₃-C-TNB)₂ (874) were provided by Dr. Dongsheng, C-Y₃-Stp₂-[(OleA)₂-K]K-Stp₂-Y₃-C (454), C-Stp₂-[(OleA)₂-K]K-Stp₂-C (49) and (LinA)₂-K-C-Stp₃-C (229) were provided by Dr. Dongsheng and Sören Reinhard [36, 37].
2.2 Methods

2.2.1 siRNA polyplex formation

The amount of oligomer ($n_{\text{oligomer}}$, nmole) for the fixed amount of nucleic acid is calculated via N/P (pronatable amines of the oligomer/phosphates of the siRNA) ratio:

$$n_{\text{oligomer}}(\text{nmole}) = \frac{m_{\text{siRNA}}(\text{ng})}{M_{\text{siRNA}}} \cdot \frac{P_{\text{siRNA}}}{N_{\text{oligomer}}} \cdot \frac{N}{P}$$

$m_{\text{siRNA}}$: weight of siRNA (ng); $M_{\text{siRNA}}$: molecular weight of siRNA; $P_{\text{siRNA}}$: amount of phosphates of siRNA; $N_{\text{oligomer}}$: amount of pronatable amines of oligomer.

Polyplexes for transfections were prepared (unless otherwise mentioned) as follows: 500 ng of siRNA and the calculated amount of oligomer at the indicated N/P ratios were separately diluted in 10 μL of 20 mM HEPES buffered 5% glucose pH 7.4 (HBG). The oligomer solution was added to the nucleic acid solution and mixed by rapid pipetting (at least 5 times) to obtain totally 20 μL of polyplex solution. The polyplexes were allowed to form for 40 min under exposure to air oxidation at room temperature in the closed Eppendorf tube.

2.2.2 Formulation of targeted combinatorial polyplexes (TCPs)

Calculations of the individual two oligomers used at N/P 16 in formation of TCPs at indicated molar ratios were made as follows.

- Protonatable nitrogens (N) for the applied oligomers in the current work were calculated excluding histidine Ns (defined as unprotonated at pH 7.4): N = 29 for 386/769, N = 29 for 689/770, N = 68 for 709/873, N = 34 for 717/874.
- The required molar amine amounts of oligomers at N/P 16 were calculated, which are 24.88 nmol nitrogens (N) for 500 ng of siRNA (in transfection). For size measurements 10 μg of siRNA were used, corresponding to 498 nmol N.
- For the following calculation of the molar amount of each oligomer, general formulas were applied as follows:
  1) $N/P_{\text{total}} = 16 = N/P_a + N/P_b$ ("a" and "b" to stand for the two oligomers).
  2) Total molar amount of nitrogen $M_{\text{total}} = N_a \times M_a + N_b \times M_b$, here N stands for the number of protonatable nitrogens, while M stands for the molar amount.
  3) The molar ratio of oligomers $M_a/M_b = R_a/R_b$
     R stands for the ratio of each oligomer (1:1 in the majority of cases).
  4) Calculation of the molar amount of each oligomer:
Materials and Methods

$M_a = 16 \times M_{total} \times N_a/(N_a + N_b \times R_b/R_a)$, and $M_b = 16 \times M_{total} \times N_b/(N_a \times R_a/R_b + N_b)$.

5) The individual N/P ratio for each oligomer (at N/P$_{total}$ = 16):

$N/P_a = 16 \times N_a/(N_a + N_b \times R_b/R_a)$, and $N/P_b = 16 \times N_b/(N_a \times R_a/R_b + N_b)$.

- As an example of TCP1 386/873 at molar ratio 40:60, the individual N/P for 386 is $16 \times 29/(29 + 68 \times 60/40) = 3.5$, for 873 it is $16 \times 68/(29 \times 40/60 + 68) = 12.5$, and the molar amount M for 386 is $24.88 \times 29/(29 + 68 \times 60/40) = 5.45$ nmol for 500 ng of siRNA.

Please note that, depending on the selected molar ratios and TCPs, the final molar ratios of thiol SH / TNB will differ. At oligomer molar ratio of 1:1, SH / TNB is 3:4 for TCP1, 2:3 for TCP2, 4:3 for TCP3, and 3:2 for TCP4.

siRNA polyplexes were prepared (unless otherwise mentioned) as follows: at the indicated N/P ratios, 500 ng of siRNA was diluted in 10 μL of HBG, and the calculated amount of the two oligomers for the designated [TNB-modified oligomer / unmodified mercapto-form of oligomer] molar ratio, were separately diluted in 5 μL of HBG. The solution of the first TNB-modified oligomer was added to the siRNA solution and mixed by rapid pipetting (at least 5 times) to obtain 15 μL of binary siRNA polyplex solution. After 30 min in the closed Eppendorf reaction tube at room temperature, the solution of the second oligomer was added to the siRNA polyplex solution, to obtain 20 μL of siRNA polyplex solution in total. The solution was placed for further 40 min at room temperature for disulfide formation.

2.2.3 Formulation of targeted lipopolyplexes (TLPs)

The individual two oligomers at N/P 16 in preparation of TLPs at indicated molar ratios were calculated as follows:

- Protonatable nitrogens (N) for the applied oligomers: N = 25 for 356, N = 13 for 49, N = 9 for 229, N = 13 for 454.

- The required molar amine amounts of oligomers at N/P 16 were calculated, which are 24.88 nmol nitrogens (N) for 500 ng of siRNA.

- For the following calculation of the molar amount of each oligomer, general formulas were applied as follows:
  1) $N/P_{total} = 16 = N/P_a + N/P_b$ ("a" and "b" to stand for the two oligomers).
  2) Total molar amount of nitrogen $M_{total} = N_a \times M_a + N_b \times M_b$, here N stands for the number of protonatable nitrogens, while M stands for the molar amount.
  3) The molar ratio of oligomers $M_a/M_b = R_a/R_b$.

R stands for the ratio of each oligomer (e.g. 356:454 = 30%:70% for TLP1 and 356:49 =
Materials and Methods

30%:70% for TLP2).

4) Calculation of the molar amount of each oligomer:
\[ M_a = 16 \times M_{\text{total}} \times \frac{N_a}{(N_a + N_b \times R_b/R_a)} \], and \[ M_b = 16 \times M_{\text{total}} \times \frac{N_b}{(N_a \times R_a/R_b + N_b)} \].

5) The individual N/P ratio for each oligomer (at N/P_{\text{total}} = 16):
\[ \frac{N}{P_a} = 16 \times \frac{N_a}{(N_a + N_b \times R_b/R_a)} \], and \[ \frac{N}{P_b} = 16 \times \frac{N_b}{(N_a \times R_a/R_b + N_b)} \].

- As an example of TLP1 containing 356:454 at molar ratio of 30%:70%, the individual N/P for 356 is \( 16 \times 25/(25 + 13 \times 70/30) = 7.2 \), for 454 it is \( 16 \times 13/(25 \times 30/70 + 13) = 8.8 \), and the molar amount M for 356 is \( 24.88 \times 25/(25 + 13 \times 70/30) = 11.25 \) nmol for 500 ng siRNA.

siRNA polyplexes were prepared (unless otherwise mentioned) as follows: at the indicated N/P ratios, 500 ng of siRNA was diluted in 10 μL of HBG, and the calculated amount of the two oligomers for the designated [targeted PEG oligomer / lipo-oligomer] molar ratio at N/P 16 were diluted in 10 μL of HBG. The oligomer solution was added to the nucleic acid solution and mixed by rapid pipetting (at least 5 times) to obtain totally 20 μL of polyplex solution. The polyplexes were allowed to form for 40 min under exposure to air oxidation at room temperature in the closed Eppendorf tube.

2.2.4 Fluorescence correlation spectroscopy (FCS)

To estimate the hydrodynamic radii of the polyplexes, fluorescence correlation spectroscopy (FCS) was used. Unlabeled control siRNA (siCtrl) was spiked with 20% of Cy5-labeled siRNA in HBG. Polyplexes containing 10 μg of siRNA for the indicated N/P ratio were prepared in 50 μL of HBG. After incubation at room temperature for 40 min to form polyplexes, the samples were diluted 1:40 in HEPES (20 mM, pH 7.4) and were measured on a home-built confocal microscope by excitation of Cy5 with a pulsed 640 nm laser (LDH-D-C-640, Picoquant, Berlin, Germany). The FCS volume was calibrated using fluorophores with known diffusion coefficients with the calculated probe volume, where the diffusion coefficients could be directly determined by fitting the autocorrelation function. Hydrodynamic radii were calculated from the diffusion coefficients using the Stokes-Einstein relationship assuming a spherical shape of the particles. A detailed description of the method could be found in the supplementary materials in [53].
2.2.5 Size and zeta potential by dynamic light scattering (DLS) measurements

Particle sizes and zeta potentials of siRNA polyplexes were measured using Zetasizer Nano ZS (Malvern Instruments, Worcestershire, U.K.). siRNA polyplexes containing 1.5 μg of nucleic acid in a total volume of 60 μL were further diluted 1:20 with HEPES buffer (20 mM, pH 7.4) before measuring in a folded capillary cell (DTS1060 or DTS1070). For size measurements, each sample was measured three times with 10 subruns at 25 °C. Zeta potential was calculated by the Smoluchowski equation, and each sample was measured 3 times with 10 to 30 subruns at 25 °C.

2.2.6 Gel shift assay

A 2.5% (w/v) agarose gel was prepared by dissolving agarose in TBE buffer (10.8 g of Trizma base, 5.5 g of boric acid, 0.75 g of disodium EDTA, and 1 L of water). After adding GelRed (Biotium, Hayward, CA, USA), the agarose gel was formed in the electrophoresis chamber. siRNA polyplexes containing 500 ng of siRNA were formed and loaded into the wells in the gel after adding 4 μL of loading buffer (6 mL of glycerine, 1.2 mL of 0.5 M EDTA, 2.8 mL of H2O, 0.02 g of bromophenol blue). Electrophoresis was performed at 120 V for 40 min and the results were recorded by UV transilluminator (Dark Hood DH-40, Biostep, Burkhardtsdorf, Germany).

2.2.7 Particle imaging by transmission electron microscopy (TEM)

A formvar-carbon 300 mesh copper grid (Ted Pella, Redding, CA, USA) was activated by mild plasma cleaning. Afterwards, one drop (10 μL) of the siRNA polyplex solution at N/P 16 (diluted in water) was placed on the grid. Excess liquid was blotted off using filter paper until the grid was almost dry. Subsequently, the copper grid was stained with 10 μL of 1% phophotungstic acid (PTA) solution (Sigma-Aldrich, Munich, Germany), and analyzed using JEM 1011 transmission electron microscope (JEOL, Tokyo, Japan) at 80 kV.

2.2.8 Atomic force microscopy (AFM)

Polyplexes containing 10 μg of siRNA and the according amount of oligomer for N/P 16 were prepared in 50 μL of HBG. Samples were incubated for 40 min to ensure complete polyplex formation. Samples were diluted 1:50 for AFM measurements in HEPES (20 mM, pH 7.4). The glass slides (diameter of 30 mm, Assistent, Sondheim, Germany) were used as negatively charged flat substrates for particles to be attached onto. After polyplex formation, 500 μL of the diluted polyplexes with positive surface charge were deposited onto the glass slide, which was mounted
Materials and Methods

to a sample plate (Agilent Technologies, Santa Clara, CA, USA) and incubated for ∼3 min, resulting in a surface coated with particles. The solution on the glass slide was subsequently replaced by the pure HEPES (20 mM, pH 7.4). After mounting the sample plate onto the AFM, the cantilever was installed into the device. Samples were imaged with the contact mode on AFM (AFM6000, Agilent Technologies, Santa Clara, CA, USA). Imaging at room temperature was performed with silicon nitride cantilevers (MSCT, nominal spring constant of 10 pN/nm, Bruker, Billerica, MA, USA). Imaging parameters were optimized for best image quality, in combination with the maintenance of the lowest possible set point to minimize damage to the samples.

2.2.9 Cell culture

As FR-expressing cell lines, murine lymphocytic leukemia cells (L1210), murine lung carcinoma cells (M109), human cervix carcinoma cells (KB), and human cervix carcinoma cells stably transfected with the eGFPLuc (enhanced green fluorescent protein/luciferase) gene (KB/eGFPLuc) were cultured in folate-free RPMI 1640 medium (Invitrogen, Karlsruhe, Germany), supplemented with 10% fetal bovine serum (FBS), 4 mM stable glutamine, 100 U/mL penicillin, and 100 μg/mL streptomycin. Human alveolar adenocarcinoma cells (A549), human mammary adenocarcinoma cells (MCF-7), and human mammary adenocarcinoma cells expressing eGFPLuc gene (MCF-7/eGFPLuc) were used as FR-deficient controls. A549 cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM), supplemented with 10% fetal calf serum, 4 mM stable glutamine, 100 U/mL penicillin, and 100 μg/mL streptomycin. MCF-7 and MCF-7/eGFPLuc cells were grown in DMEM, supplemented with 20% FBS, 4 mM stable glutamine, 100 U/mL penicillin, and 100 μg/mL streptomycin. The cells were cultured in ventilated flasks inside incubators at 37°C with 5% CO2 in a humidified atmosphere. Cell lines were grown to 80 - 90% confluent and harvested.

2.2.10 Cellular association and internalization study

For flow cytometric measurements, unlabeled control siRNA (siCtrl) was spiked with 20% of Cy5-labeled siRNA (Cy5-siAHA1) in HBG. L1210 cells were seeded onto 24-well plates at a density of $2 \times 10^5$ cells/well in 450 μL of fresh growth medium. KB, M109, A549 and MCF-7 cells were seeded onto 24-well plates at a density of $5 \times 10^4$ cells/well, and 24 h later the medium was replaced by 450 μL of fresh growth medium. The cells were treated with 50 μL of siRNA polyplexes containing 2.5 μg of siRNA and corresponding amount of oligomer at N/P 16 (final siRNA concentration: 370 nM). The 24-well plates were incubated on ice for 45 min for cellular
association, or at 37 °C for 4 h for cellular internalization. Then the samples were prepared for flow cytometric measurements.

2.2.11 Ligand competition study
KB cells were seeded onto 24-well plates at a density of 5 × 10⁴ cells/well, and 24 h later the medium was replaced with 450 µL of fresh growth medium, or 450 µL of fresh growth medium containing 100 µM MTX or 100 µM folate, and cells were incubated at 37 °C for 30 min. Then 50 µL of polyplexes containing 2.5 µg of siRNA and indicated amount of oligomer at N/P ratio of 16 (final siRNA concentration: 370 nM) were applied onto the cells. The cells were placed in the incubator at 37 °C for 4 h before flow cytometric measurement.

2.2.12 Fluorescence resonance energy transfer (FRET) intensity in Cy5/TAMRA double-labeled siRNA
KB or L1210 cells were seeded onto 12-well plates at a density of 5 × 10⁴ cells/well, and 24 h later the medium was replaced with 900 µL of fresh growth medium. The cells were treated with 100 µL of polyplexes containing 5 µg of Cy5/TAMRA double-labeled siRNA at N/P 16 (final siRNA concentration: 370 nM) for 45 min. The cells were placed in the incubator at 37 °C for 2 and 4 h before flow cytometric measurement.

2.2.13 Flow cytometry
After transfection, the medium was removed and cells were washed twice with PBS. KB, M109 and MCF-7 cells were trypsinized, and then trypsin was inactivated with 1000 µL of FACS buffer (10% FBS in PBS). The cells were centrifuged (1000 rpm; 5 min) and then resuspended in 600 µL of FACS buffer. For cellular internalization study, the samples were immediately mixed with DAPI at a final concentration of 1 ng/µL before flow cytometry. The amount of Cy5-positive cells was counted through excitation of Cy5 at 635 nm and detection of emission at 665/20 nm by Cyan ADP flow cytometer (Beckman Coulter, Fullerton, CA, USA). The results were recorded by Summit software V4.3.02 (Summit, Jamesville, NY, USA) and evaluated using FlowJo V10.0.6 software (FlowJo, Ashland, OR, USA). For FRET analysis, fluorescence intensity of the cells was measured by BD LSRFortessa X-20 (BD Biosciences, Franklin Lakes, NJ, USA) and evaluated using FACSDiva software (BD Biosciences, Franklin Lakes, NJ, USA) at excitation wavelength of 488 nm and a 660/20 nm filter. All experiments were performed in triplicates.
2.2.14 Intracellular distribution of siRNA polyplexes by time-lapse imaging

5 × 10^5 KB cells were seeded on 35 mm micro-dishes (ibidi GmbH, Martinsried, Germany) and were incubated with CellLight Late Endosomes-RFP and CellLight Lysosomes-GFP (both from Molecular Probes, Eugene, OR, USA) overnight before measurements. Unlabeled control siRNA (siCtrl) was spiked with 30% of AF 647-labeled siRNA in HBG. Polyplexes containing 5 μg of siRNA for N/P 16 were prepared in 100 μL of HBG. The medium was replaced with 900 μL of fresh medium and 100 μL of polyplexes containing 5 μg of siRNA at N/P 16 (final siRNA concentration: 370 nM). The nuclei were stained with 10 μL/mL of Hoechst 33342 (Dojindo Laboratories, Kumamoto, Japan) for 3 min. The intracellular distribution of siRNA was observed using time-lapse imaging by CLSM (LSM 880, Carl Zeiss, Oberkochen, Germany) for 16 h with a Plan-Apochromate 63×/1.4 oil objective lens, diode laser (405 nm) for Hoechst 33342, Ar laser (458 nm/488 nm/514 nm) for CellLight Late Endosomes-GFP, DPSS laser (561 nm) for CellLight Late Endosomes-RFP and He–Ne laser (633 nm) for AF 647. ZEN 2.1 software (Carl Zeiss, Oberkochen, Germany) was used to process the imaging data.

2.2.15 Endosomal escape of siRNA polyplexes by 3D image reconstruction

5 × 10^5 KB cells were seeded on 35 mm micro-dishes (ibidi GmbH, Martinsried, Germany) and were incubated with CellLight Late Endosomes-RFP and CellLight Lysosomes-GFP (both from Molecular Probes, Eugene, OR, USA) overnight before measurements. Unlabeled control siRNA (siCtrl) was spiked with 30% of AF 647-labeled siRNA in HBG. Polyplexes containing 5 μg of siRNA for N/P 16 were prepared in 100 μL of HBG. The medium was replaced with 900 μL of fresh medium, and 100 μL of polyplex containing 5 μg of siRNA at N/P 16 was added (final siRNA concentration: 370 nM). After transfection for 45 min, the intracellular distribution of siRNA was observed using 3D reconstruction from serial images from single cell by super-resolution CLSM (LSM 880 combined, Carl Zeiss, Oberkochen, Germany) at 4 h with the abovementioned lens and lasers.
2.2.16 Colocalization analysis of siRNA polyplexes and endolysosomal vesicles.

$5 \times 10^4$ KB cells were seeded onto 8-well micro-chamber slides (ibidi GmbH, Martinsried, Germany). The medium was replaced by 180 μL of fresh medium 24 h later. Unlabeled control siRNA (siCtrl) was spiked with 30% of AF 647-labeled siRNA in HBG. Late endosomes and lysosomes were labeled with LysoTracker Green (Molecular Probes, Eugene, OR, USA) and the cells were transfected with 20 μL of polyplexes (final concentration: 370 nM at N/P 16) for 45 min. The transfection medium was removed, and then cells were washed with 200 μL of PBS and fixed with 4% paraformaldehyde. Nuclei were stained with DAPI. The intracellular distribution of siRNA was observed by CLSM (LSM 880, Carl Zeiss, Oberkochen, Germany) at 2 and 4 h using a 63×/1.4 oil objective lens, diode laser (405 nm) for DAPI, Ar laser (458 nm/488 nm/514 nm) for LysoTracker Green and He–Ne laser (633 nm) for AF 647.

Colocalization ratios of AF 647-labeled siRNA with late endosomes and lysosomes were calculated using ZEN 2.1 software as follows:

$$\text{colocalization ratio} = \frac{\text{AF 647 pixels}_{\text{colocalization}}}{\text{AF 647 pixels}_{\text{total}}}$$

where $\text{AF 647 pixels}_{\text{colocalization}}$ represents the number of AF 647 pixels overlapping with LysoTracker Green, and $\text{AF 647 pixels}_{\text{total}}$ represents the total number of AF 647-positive pixels in the cell. For each condition, colocalization ratios were calculated from 5 individual cells.

2.2.17 Fluorescence resonance energy transfer (FRET) imaging in Cy5/TAMRA double-labeled siRNA

$5 \times 10^4$ KB cells were seeded onto 8-well micro-chamber slides (ibidi GmbH, Martinsried, Germany) and labeled with CellLight Lysosomes-GFP (Molecular Probes, Eugene, OR, USA) overnight before measurements. The medium was replaced by 180 μL of fresh medium, and the cells were transfected with 20 μL of polyplexes containing Cy5/TAMRA double-labeled siRNA (final concentration: 370 nM at N/P 16) for 45 min. The transfection medium was removed, and then cells were washed with 200 μL of PBS and fixed with 4% paraformaldehyde. Nuclei were stained with DAPI. The FRET signal of siRNA was observed by CLSM (LSM 880, Carl Zeiss, Oberkochen, Germany) at 1 and 24 h using a 561 nm excitation laser and the lambda stacks were obtained within a range of 565 to 700 nm at a bandwidth of 4.5 nm. The spectral images obtained were linearly unmixed to Cy5 and TAMRA spectra.
2.2.18 Pre-embedding immuno-labeling for TEM

To visualize the siRNA molecules for immuno-electron microscopy, the biotinylated siRNA (740 nM) was first associated with 10 nm neutravidin-gold conjugate (at molecular ratio of 3:1) for 10 min, followed by complexation with the calculated amount of oligomers at N/P 16 in HBG. KB cells were seeded onto round glass coverslips (diameter of 12 mm, Menzel Gläser, Braunschweig, Germany) in 35 mm petri dishes and grown to 80–90% confluence. Thereafter, the coverslips were transferred into wells of 24-well plate and incubated with siRNA polyplexes in culture medium for 15 min, 1 h or 4 h at 37 °C. After incubation, the cells were washed and fixed with PLP fixative according to McLean and Nagane [61] (2% formaldehyde, 0.01 M sodium periodate, 0.075 M lysine in 0.075 M sodium phosphate buffer) at room temperature for 2 h. Cells were slightly permeabilized with 0.01% saponin (Sigma-Aldrich, St. Louis, MO, USA) supplemented with 0.1% BSA in 0.1 M sodium phosphate buffer for 8 min. After permeabilization, the cells were stained with mouse IgG against FR (R&D Systems, Minneapolis, MN, USA) for 1 h and Protein G-6 nm gold conjugate (1:40) (Aurion Immuno Gold Reagents & Accessories, Wageningen, Netherlands) for an additional 1 h. Then the cells were washed, postfixed with 1% osmium tetroxide in the 0.1 M sodium cacodylate buffer (pH 7.4) for 1 h at room temperature, and dehydrated with ethanol. The specimens were embedded in epoxy resin (TAAB Laboratories Equipment Ltd., Reading, UK), cut into ultrathin sections, and contrasted with uranyl acetate and lead citrate. The sections were examined with Tecnai G2 Spirit BioTWIN transmission electron microscope (FEI, Eindhoven, Netherlands) at 120 kV. Electron microphotos were analyzed and processed with Photoshop CS6 (Adobe, San Jose, CA, USA).

2.2.19 Gene silencing mediated by GFP-siRNA in vitro

Cells were seeded in 100 μL of medium using 96-well plates at a density of 4 × 10^3 cells for KB/eGFPLuc and 5 × 10^3 cells for MCF-7/eGFPLuc per well 24 h prior to the experiment. Before the treatment, medium was replaced with 80 μL of fresh growth medium. siGFP and siGFP-Inf7 were used for silencing of the eGFPLuc protein in comparison with control siRNA (siCtrl and siCtrl-Inf7). Cells were transfected with 20 μL of siRNA polyplexes containing 500 ng of siRNA at certain N/P ratios (final siRNA concentration: 370 nM) at 37 °C for 45 min, then the medium was replaced by 100 μL of fresh growth medium. After incubation for 48 h, the medium was removed and 100 μL of cell culture lysis reagent (Promega, Mannheim, Germany) was added per well. Luciferase activity was measured using the luciferase assay kit (Promega, Mannheim, Germany) and recorded on a Centro LB 960 plate reader luminometer (Berthold, Bad Wildbad, Germany). The relative light units (RLU) are presented as percentage of the luciferase gene activity.
expression obtained with untreated control cells.

2.2.20 Cytotoxicity mediated by EG5 knockdown or MTX conjugates

$4 \times 10^3$ KB or M109 cells per well were seeded into 96-well plates in 100 μL of growth medium 24 h prior to the treatment. Medium was replaced by 80 μL of fresh medium and 20 μL of polyplexes (at N/P 16 with siEG5, siCtrl, siEG5-Inf7, or siCtrl-Inf7; final concentration of siRNA: 370 nM), plain oligomer, or MTX solution in HBG. After incubation for 24 h (37 °C, 5% CO$_2$), medium was replaced by 100 μL of fresh growth medium and the cells were maintained for 24 h (37 °C, 5% CO$_2$). MTT assay (Life Technologies, Darmstadt, Germany) for metabolic activity was performed to evaluate the cell viability and measured by SpectraFluor Plus microplate reader (Tecan, Männdorf, Switzerland). The experiments were performed in triplicates and the cell viability was calculated as percentage compared to untreated control cells.

2.2.21 Evaluation of mitotic aster formation

KB or M109 cells ($1 \times 10^4$/well) were seeded in 200 μL of fresh growth medium using 8-well Lab-Tek chamber slides (Nunc, Penfield, NY, USA). The medium was replaced by 180 μL of fresh medium 24 h later. The cells were transfected with 50 μL of polyplexes containing 1.15 μg of siRNA (with siEG5, siCtrl, siEG5-Inf7, or siCtrl-Inf7; final concentration: 370 nM at N/P 16) and incubated for 48 h (37 °C, 5% CO$_2$). The transfection medium was removed, and then cells were washed with 200 μL of PBS and fixed with 4% paraformaldehyde. Nuclei were stained with DAPI (1 μg/mL) and observed under Axiovert 200 fluorescence microscope (Carl Zeiss, Oberkochen, Germany).

2.2.22 Quantitative real-time polymerase chain reaction (qRT-PCR)

qRT-PCR was performed to determine the mRNA level of EG5 gene in transfected cells. KB or L1210 cells ($1.5 \times 10^5$/well) were seeded in 900 μL of medium onto 6-well plates. The cells were treated with 100 μL of siRNA polyplexes (N/P 16) with a final siRNA concentration of 370 nM and incubated for 24 h. Total RNA was isolated by miRCURY RNA Isolation Kit (Exiqon, Vedbaek, Denmark) followed by reverse transcription using Transcriptor High Fidelity cDNA Synthesis Kit (Roche, Mannheim, Germany) according to the manufacturers’ protocols. qPCR was performed in triplicates on a LightCycler 480 system (Roche, Mannheim, Germany) using UPL Probes (Roche, Mannheim, Germany) and Probes Master (Roche, Mannheim, Germany) with GADPH as housekeeping gene. The following probes and primer sequences were used:
Materials and Methods

human or murine GAPDH (ready-to-use in UPL), human EG5 (UPL Probe #53) (forward: CATCCAGGTGGTGGTGAGAT, reverse: TATTGAATGGGCGCTAGCTT), and murine EG5 (UPL Probe #100) (forward: TTCCCCTGCATCTTTCAATC, reverse: TTCAGGCTTATTCATTAGTTCTTTTG). Results were analyzed by the ΔC_T method. C_T values of GAPDH were subtracted from C_T values of EG5. ΔC_T values of transfected cells were calculated as percentage relative to untreated control cells.

2.2.23 Tumor mouse model

Female 8-week-old nude mice, Rj: NMRI-nu (nu/nu) (Janvier, Le Genest-Saint-Isle, France), were housed in isolated ventilated cages under specific pathogen-free condition with a 12 h light/dark interval, and were acclimated for at least 7 days prior to experiments. Food and water were provided ad libitum. Animals were injected with 5 × 10^6 KB or 0.5-2 × 10^6 L1210 cells subcutaneously (s.c.) for biodistribution study, and were injected with 5 × 10^6 KB or 1 × 10^6 L1210 cells subcutaneously for EG5 gene silencing assay in vivo. The body weight was recorded, and the tumor volume was measured by caliper and calculated as \[0.5 \times (\text{longest diameter}) \times (\text{shortest diameter})^2\] as stated by Xu et al. [62]. All animal experiments were performed according to guidelines of the German law for the protection of animal life and were approved by the local animal ethics committee.

2.2.24 Biodistribution study

For near infrared (NIR) in vivo imaging, unlabeled control siRNA (siCtrl) was spiked with 50% of Cy7-labeled siRNA (Cy7-siAHA1) in HBG. When tumors reached the size of 500–800 mm³, the mice (n = 3-4/per group) were anesthetized with 3% isoflurane in oxygen. siRNA polyplexes containing 50 µg of Cy7-labeled siRNA (N/P 16) in 50 µL of HBG were injected intratumorally (i.t.), or in 250 µL of HBG were injected intravenously (i.v.), and fluorescence was measured with a CCD camera. Animals were sacrificed for ex vivo imaging of tumors and organs at different time intervals after injection. For evaluation of images, efficiency of fluorescence signals was analyzed, after color bar scales were equalized using IVIS Lumina system with Living Image software 3.2 (Caliper Life Sciences, Hopkinton, MA, USA).
2.2.25 Antitumoral potency mediated by EG5 knockdown and MTX conjugates

The animals were randomly divided into 6 groups (n = 6), and 2 days after inoculation of tumor cells, the animals were injected i.t. with 50 µL of polyplexes containing 50 µg of siRNA at N/P 16, corresponding amount of plain oligomer or methotrexate. Treatments were applied on day 2, 4, 7, 10, 14 and 17. Tumor sizes of the animals were monitored. Animals were sacrificed after the tumor size reached 1000 mm³, and Kaplan–Maier survival analysis was performed to compare the lifetime after treatments among different groups.

2.2.26 Gene silencing mediated by EG5-siRNA in vivo

When tumors reached 500 mm³, mice (n = 5/per group) were injected i.v. with polyplexes containing 50 µg of siRNA (at N/P 16 with siEG5, siCtrl, siEG5-Inf7, or siCtrl-Inf7) 48 and 24 h before euthanasia. As a part of terminal procedure, blood samples were obtained by cardiac puncture for blood biochemistry examination. After tumors were harvested and homogenized, total RNA was extracted using Trifast (Peqlab, Erlangen, Germany) according to the manufacturer’s protocol. The reverse transcription and qRT-PCR was performed as aforementioned.

2.2.27 Blood biochemistry examinations

To isolate plasma, blood samples were collected in EDTA-coated tubes (Multivette 600, Sarstedt, Nümbrecht, Germany) and centrifuged at 3000 rpm for 7 minutes. The supernatant was analyzed for clinical biochemistry parameters: alanine aminotransferase (ALT), aspartate aminotransferase (AST), blood urea nitrogen (BUN) and creatinine in the Clinic of Small Animal Medicine, Faculty of Veterinary Medicine, Ludwig-Maximilians-Universität München.

2.2.28 Statistical analysis

Statistical analysis of the results (mean ± SEM) was evaluated by unpaired t test: *p<0.05; **p<0.01; ***p<0.001.
3 Results

3.1 Glutamylated MTX-conjugated nanoplexes

3.1.1 Oligomer structures

This chapter has been partly adapted from:

As described previously by Lächelt et al. [50], based on solid-phase-supported synthesis method [35, 63] multiple copies of the artificial oligoamino acid succinoyl tetraethylene pentamine (Stp) as a cationic backbone were combined together with α-amino acids, PEG segment and bifunctional MTX ligand to generate sequence-defined monodisperse peptide-like oligomers for siRNA delivery [50] (Figure 3.1.1A). A two-armed structure was linked by lysine, in which each arm was composed of 4 Stp and a terminal cysteine. In the center of the two-armed core, PEG comprising 24 ethylene oxide units was coupled. MTX was attached via the γ- (638-641), or α-carboxy group (642) of glutamic acid to the exposed part of the PEG segment. For assessment of polyglutamylation-related activity of MTX conjugates, 2 (639), 4 (640) or 6 (641) glutamic acid units between the γ-carboxy group of MTX and the PEG segment had been introduced. Structures are illustrated in Figure 3.1.1B and listed in Table 3.1.1. For control structures, folate was used as non-toxic monofunctional targeting ligand (356) and alanine as a non-functional ligand substitute (188).
Figure 3.1.1. Polyplexes with bifunctional polyglutamylated MTX ligand for siRNA delivery. (A) Schematic diagram of the siRNA polyplex formulation. (B) Overview of the oligomers with MTX polyglutamates. The synthetic procedures were described in Lächelt et al. [50]. A two-armed structure was linked by lysine, in which each arm composed of 4 Stp and a terminal cysteine. MTX was attached via γ- (638-641), or α-carboxy group (642) to the exposed part of the PEG segment. “K” represents lysine. “+” in gray represents a cationic oligoamino acid building block (Stp). “~” represents dPEG₂₄ motifs.

Table 3.1.1. The sequences of oligomers.a

<table>
<thead>
<tr>
<th>Oligomer</th>
<th>Sequence (C→N)</th>
<th>Abbreviation</th>
</tr>
</thead>
<tbody>
<tr>
<td>188</td>
<td>A-dPEG₂₄-K(Stp₄-C)₂</td>
<td>A- Stp</td>
</tr>
<tr>
<td>356</td>
<td>C-Stp₄-K(Stp₄-C)-dPEG₂₄-FolA</td>
<td>FolA- Stp</td>
</tr>
<tr>
<td>638</td>
<td>K(dPEG₂₄-MTX)-K(Stp₄-C)₂</td>
<td>MTX- Stp</td>
</tr>
<tr>
<td>639</td>
<td>K(dPEG₂₄-E₂-MTX)-K(Stp₄-C)₂</td>
<td>2E-MTX- Stp</td>
</tr>
<tr>
<td>640</td>
<td>K(dPEG₂₄-E₄-MTX)-K(Stp₄-C)₂</td>
<td>4E-MTX- Stp</td>
</tr>
<tr>
<td>641</td>
<td>K(dPEG₂₄-E₆-MTX)-K(Stp₄-C)₂</td>
<td>6E-MTX- Stp</td>
</tr>
<tr>
<td>642</td>
<td>K(dPEG₂₄-αMTX)-K(Stp₄-C)₂</td>
<td>αMTX- Stp</td>
</tr>
</tbody>
</table>

a A, alanine; C, cysteine; E, glutamic acid; K, lysine; Stp, succinoyl tetraethylen pentamine; dPEG₂₄, poly(ethylene glycol); FolA, folic acid; MTX, methotrexate. Details can be found in [50].
3.1.2 Physicochemical characteristics of MTX-conjugated siRNA polyplexes

siRNA was formulated with MTX conjugates at different N/P ratios and measured the particle sizes by fluorescence correlation spectroscopy (FCS). As shown in Table 3.1.2 and Figure 3.1.2, the hydrodynamic diameter for different oligomers at N/P 16 was ranging between 5.2 to 6.6 nm. Similarly, polyplexes formed at different N/P ratios did not affect the size significantly, for example, MTX conjugate 640 formed polyplexes with the size between 5.6 to 6.4 nm at different N/P ratios (Figure 3.1.3).

Table 3.1.2. Hydrodynamic diameter ($d_h$) of polyplexes loaded with Cy5-labeled siRNA at different N/P ratios determined by fluorescence correlation spectroscopy (FCS).

<table>
<thead>
<tr>
<th>Oligomer</th>
<th>N/P</th>
<th>$d_h$ (nm)</th>
<th>Diffusion Coefficient ($\mu$m$^2$/s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cy5-siRNA</td>
<td>-</td>
<td>4.6 (±0.2)</td>
<td>96 (±2) $^b$</td>
</tr>
<tr>
<td>356</td>
<td>16</td>
<td>6.6 (±0.3)</td>
<td>66 (±1) $^a$</td>
</tr>
<tr>
<td>638</td>
<td>16</td>
<td>5.6 (±0.3)</td>
<td>79 (±1) $^a$</td>
</tr>
<tr>
<td>639</td>
<td>16</td>
<td>5.6 (±0.3)</td>
<td>78 (±1) $^a$</td>
</tr>
<tr>
<td>641</td>
<td>16</td>
<td>5.2 (±0.2)</td>
<td>86 (±2) $^a$</td>
</tr>
<tr>
<td>640</td>
<td>3</td>
<td>5.6 (±0.3)</td>
<td>79 (±1) $^a$</td>
</tr>
<tr>
<td></td>
<td>10</td>
<td>6.2 (±0.3)</td>
<td>70 (±2) $^a$</td>
</tr>
<tr>
<td></td>
<td>16</td>
<td>6.4 (±0.3)</td>
<td>68 (±1) $^a$</td>
</tr>
<tr>
<td></td>
<td>20</td>
<td>5.8 (±0.3)</td>
<td>75 (±2) $^a$</td>
</tr>
<tr>
<td></td>
<td>28</td>
<td>5.8 (±0.3)</td>
<td>75 (±2) $^a$</td>
</tr>
</tbody>
</table>

$^a$ Errors for the diffusion coefficients are given as Jacobians of the fit. They do not contain any information about systematic deviations.

$^b$ The error for Cy5-siRNA was determined from six independent measurements of the siRNA.

$^c$ The absolute errors of the hydrodynamic diameters of the polyplexes were calculated as described in supplementary methods in [53]. The experiments were performed in collaboration with Dr. Lena Voith von Voithenberg (Department of Chemistry, Ludwig-Maximilians-Universität München).
Figure 3.1.2. FCS measurements of Cy5-labeled polyplexes at N/P 16 in comparison to free Atto655 and Cy5-siRNA (Cy5-siAHA1). (A) As an overview, the normalized autocorrelation functions and weighted residuals for the fitted data for free Cy5-siRNA, and 356, 638, 639, 641, and 642 polyplexes. (B-F) Comparison of normalized autocorrelation functions of Atto655, Cy5-siRNA, and (B) 356, (C) 638, (D) 639, (E) 641, (F) 642 polyplexes. The experiments were performed in collaboration with Dr. Lena Voith von Voithenberg (Department of Chemistry, Ludwig-Maximilians-Universität München).
Figure 3.1.3. FCS measurement of Cy5-labeled 640 polyplexes at different N/P ratios in comparison to free Cy5 and Cy5-siRNA (Cy5-siAHA1). (A) As an overview, the normalized autocorrelation functions and weighted residuals for the fitted data of free Cy5-siRNA, and 640 polyplexes at different N/P ratios. (B-F) Comparison of normalized autocorrelation functions of Cy5, Cy5-siRNA, and the polyplexes at (B) N/P 3, (C) N/P 10, (D) N/P 16, (E) N/P 20, and (F) N/P 28. The experiments were performed in collaboration with Dr. Lena Voith von Voithenberg (Department of Chemistry, Ludwig-Maximilians-Universität München).
Previous findings indicated that such very small oligomer/siRNA nanoplexes are not suitable for standard analysis by dynamic laser light scattering (DLS) [64-66]. Therefore, to further study the morphology of 640 siRNA polyplexes, we carried out atomic force microscopy (AFM) and transmission electron microscopy (TEM) measurements. As shown in Figure 3.1.4 and 3.1.5, these images indicated the formation of homogeneous spherical nanoparticles with size (7.7 ± 0.8 nm by AFM; 6.8 ± 0.2 nm by TEM) in a range similar to the FCS measurements. Also in the FCS experiments, no aggregation was observed for these polyplexes. Hence, all evidence indicates that the siRNA polyplexes were shielded and stable.

**Figure 3.1.4.** AFM images of siRNA polyplexes at N/P 16: (A) 356 polyplexes (arrows): d = 5.3 ± 0.6 nm; (B) 640 polyplexes (arrows): d = 7.7 ± 0.8 nm. The light intensity reflects the height of nanoparticles. The scale bars represent 50 nm. The experiments were performed in collaboration with Dr. Rong Zhu (Institute of Biophysics, Johannes-Kepler-Universität Linz).

**Figure 3.1.5.** TEM image of 640 siRNA polyplexes at N/P 16. d = 6.8 ± 0.2 nm. The scale bar represents 20 nm. The experiment was performed in collaboration with Susanne Kempter (Faculty of Physics, Ludwig-Maximilians-Universität München).

To examine the effect of PEGylation on the surface charge of polyplexes, zeta potential of polyplexes at various N/P ratios was measured (Table 3.1.3). At N/P 16, zeta potential values of the ligand-equipped polyplexes remained close to neutrality, with a distribution between 0.2 to 2.5 mV. In the case of 640, at N/P 3, the zeta potential was 0.03 mV, and remained close to neutral with increasing N/P ratio. Finally, even at very high ratio of oligomer over siRNA (N/P 28), the zeta potential was neutral, suggesting that PEGylation successfully shielded the surface charge of siRNA polyplexes.
Table 3.1.3. Zeta potential values of siRNA polyplexes at different N/P ratios determined by dynamic light scattering (DLS) measurements.

<table>
<thead>
<tr>
<th>Oligomer</th>
<th>N/P</th>
<th>Zeta Potential (mV)</th>
</tr>
</thead>
<tbody>
<tr>
<td>638</td>
<td></td>
<td>0.9 (± 0.3)</td>
</tr>
<tr>
<td>639</td>
<td>16</td>
<td>0.2 (± 0.2)</td>
</tr>
<tr>
<td>641</td>
<td></td>
<td>0.6 (± 0.1)</td>
</tr>
<tr>
<td>642</td>
<td></td>
<td>2.5 (± 1.2)</td>
</tr>
<tr>
<td>640</td>
<td>3</td>
<td>0.03 (± 0.04)</td>
</tr>
<tr>
<td></td>
<td>10</td>
<td>-3.5 (± 0.6)</td>
</tr>
<tr>
<td></td>
<td>16</td>
<td>1.3 (± 0.8)</td>
</tr>
<tr>
<td></td>
<td>20</td>
<td>3.1 (± 0.4)</td>
</tr>
<tr>
<td></td>
<td>28</td>
<td>-1.6 (± 0.9)</td>
</tr>
</tbody>
</table>

3.1.3 MTX as targeting ligand for receptor-mediated uptake

It is recognized that folates and antifolates are mainly internalized into the cells either through folate receptor (FR) or reduced folate carrier (RFC). To validate targeting capacity of the MTX-conjugated siRNA polyplexes, we used fluorescent Cy5-labeled siRNA, and studied the binding profile with flow cytometry. To investigate selective targeting ability of MTX conjugates against FR, we sought to take advantage of the two cancer cell lines, FR-α-rich KB cells [67] and FR-deficient A549 cells [68-70]. Comparison of relative binding efficiency of fluorescently labeled folate in both cell lines is shown in Figure 3.1.6.

Figure 3.1.6. Binding activity of fluorescein-labeled folate ligand in different cell lines measured by flow cytometry.
KB and A549 cells were treated with MTX-based 640 siRNA polyplexes, folate-based 356 siRNA polyplexes and non-targeted alanine control 188 siRNA polyplexes formed at N/P 16 for 45 min on ice, and then binding of the polyplexes was analyzed by flow cytometry (Figure 3.1.7). For the alanine-substituted control 188, siRNA polyplexes barely bound to both cell lines (<1% positive cells). Generally, the folate-substituted control conjugate 356 and MTX oligomer conjugates (638-642) exhibited strong cellular association in FR-rich KB cells. The binding rate of tetraglutamyl-MTX conjugate 640 (67%) was comparable to that of folate substituted control conjugate 356 (71%). The binding levels for the rest of MTX conjugates in KB cells were similar, which were lower than the level for 356. On the other hand, in FR-deficient A549 cells, the uptake capacity of 356 was significantly reduced (18% positive cells), and MTX conjugates (638-642) all failed to bind to the A549 cells (<3% positive cells), supporting the FR-specific cellular association with MTX conjugates.

Figure 3.1.7. The receptor association capacity of MTX conjugates (638-642) was evaluated by comparing the binding of siRNA polyplexes by FR-overexpressing KB vs. FR-deficient A549 cells. The amount of Cy5-positive cells was analyzed through excitation of the dye at 635 nm and detection of emission at 665/20 nm by flow cytometry. 188 as a negative alanine substituted control, and 356 as folate-conjugated control were used for comparison with MTX conjugates.

To prove that the binding of the polyplexes to the cells is ligand-dependent, the competition assay with free ligands was carried out. For this, KB cells were pretreated with folate or MTX, and then treated the cells with 640 siRNA polyplexes or 356 siRNA polyplexes. As implicated by flow cytometry analysis (Figure 3.1.8), if KB cells were pre-incubated with excess of free MTX (100 μM), uptake level of MTX conjugate 640 was reduced by 53%, as MTX ligands of 640 competed with free MTX for limited receptors. Since FR has several-hundred-fold higher binding affinity for folate than for MTX [71], cellular uptake of folate conjugate 356 was not influenced by free MTX. Nevertheless, in the presence of free folate (100 μM), cellular binding of 356 and 640 was almost completely inhibited by 90% and 99%, respectively. In comparison, the binding capacity of alanine control 188 was extremely low under either condition. Based on the observations that the MTX conjugates bind to the FR-expressing KB cells in a receptor-specific fashion, and the binding was reversed by pre-incubation with excess free folate or MTX, these cellular association studies demonstrated that MTX oligomer conjugates target the KB cells mainly through the FR.
3.1.4 Gene silencing efficiency

After showing that the MTX-modified oligomer/siRNA polyplexes utilized FR for cellular association, next their ability to be taken up by the cells and induce target gene silencing was measured. To validate this, siRNA targeting eGFP (siGFP) or control siRNA (siCtrl) to transfect the cells stably expressing eGFP-Luciferase (eGFPLuc) fusion protein was used, and gene silencing of siRNA polyplexes via luciferase activity was evaluated by luminometric analysis. Previous studies with similar oligomers indicated that these siRNA polyplexes faced the problem of endosomal degradation—they are too small to effectively release into the cytosol [33]. Hence, to improve endosomal escape of siRNA polyplexes, the influenza virus haemagglutinin subunit 2 (HA2) variant Inf7 as pH-specific endosome fusion peptide was coupled to the 5' end of siRNA sense strand [33, 72]. As shown in Figure 3.1.9, glutamyl-MTX conjugates (638-642) containing Inf7-modified siGFP (siGFP-Inf7) at N/P 16 exhibited significant gene silencing efficiency in KB/eGFPLuc cells, as 84-93% of luciferase activity was suppressed. Among MTX conjugates, 640 (4E-MTX-Stp) polyplexes provided the most potent gene silencing activity (93%). In contrast, there was no silencing effect for siRNA polyplexes of alanine control 188, furthermore highlighting the specificity provided by the MTX targeting ligand. The luciferase activity in KB/eGFPLuc cells treated with controls, including siCtrl-Inf7 polyplexes, siGFP without Inf7 or plain MTX oligomers were similar, 49-67% compared to untreated cells (Figure 3.1.9 and 3.1.10).
Results

Figure 3.1.9. Gene silencing efficiency of MTX conjugates containing eGFP-targeted siRNA (siGFP) or control siRNA (siCtrl) in KB cells expressing eGFPLuc protein (KB/eGFPLuc cells). MTX conjugates were incorporated with different glutamic acid units (638-642) at N/P 16. Plain oligomers were added in concentrations corresponding to the concentrations of the respective polyplexes at the indicated N/P values. siRNA was modified with the endosomolytic peptide Inf7.

Figure 3.1.10. Gene silencing efficiency with siGFP or siCtrl (both without Inf7 peptide) in FR-overexpressing KB/eGFPLuc cells or FR-deficient MCF-7/eGFPLuc cells using MTX conjugate (640) or alanine substituted control (188) at different N/P ratios.

Figure 3.1.11. Gene silencing efficiency in FR-overexpressing KB/eGFPLuc cells (left) or FR-deficient MCF-7/eGFPLuc cells (right) using MTX conjugate (640) at different N/P ratios. siRNA was modified with the endosomolytic peptide Inf7.
Instead of displaying a RNAi effect, the reduced luciferase activity here demonstrated the intrinsic cytotoxicity of MTX ligands by inhibiting DHFR. Looking at Figure 3.1.11, in KB/eGFPLuc cells, silencing activity of tetr glutamylated MTX analogue 640 was increased while N/P ratio was higher; however, the luciferase expression level in cells treated with siCtrl-Inf7 was not altered at various N/P ratios. More importantly, in comparison with FR-positive KB/eGFPLuc cells, transfections with folate conjugate (356) or MTX conjugate (640) containing siGFP-Inf7 in FR-negative MCF-7/eGFPLuc cells did not have any impact on luciferase expression or possible cytotoxicity. Taken together, the gene silencing assay further indicated that MTX targeting allows the siRNA polyplexes to access the cytoplasm of the cells via specific FR-mediated endocytosis. MTX-conjugated oligomers complexed with Inf7-modified siRNA, especially 640, showed not only striking targeted gene-specific silencing ability, but also tissue-specific cytotoxic potential mediated by glutamylated MTX.
3.1.5 Augmented cytotoxicity by MTX conjugates and EG5 gene knockdown

As mentioned above, MTX conjugates facilitate their cytotoxic effects by inhibiting DHFR, and the inhibition potency is attributed to the glutamylation degree of MTX conjugates [50]. The next question is, whether the cytotoxicity could be enhanced by using MTX-conjugated oligomers in combination with antitumoral siRNA. For this purpose, MTX-conjugated oligomers were exploited to carry siRNA against EG5 (siEG5-Inf7), which is able to block mitosis. As shown in Figure 3.1.12A, MTT assay reflected that all glutamyl-MTX conjugates were cytotoxic in FR-expressing KB cells compared to alanine (188) or folate-substituted control (356). The cytotoxicity of the conjugates was elevated with an increasing degree of polyglutamylation, and notably, 639 (2E-MTX-Stp), 640 (4E-MTX-Stp) and 641 (6E-MTX-Stp) were more toxic compared to free MTX. Meanwhile, in FR-negative MCF-7 cells, no similar cytotoxic effects induced by MTX-conjugated or folate-substituted oligomers were found (Figure 3.1.13 and 3.1.14).

![Figure 3.1.12. Transfection with Inf7 peptide-modified EG5-targeted siRNA (siEG5-Inf7) or control siRNA (siCtrl-Inf7) polyplexes at N/P 16 in KB cells. (A) MTT assay in KB cells after transfection with MTX conjugates (638-642), alanine conjugate (188) or folate conjugate (356). Free MTX or plain oligomer was applied in concentration corresponding to that of siRNA polyplexes. (B) mRNA level of EG5 gene measured by qRT-PR after transfection with MTX conjugate (640) or folate control (356), GAPDH was used as housekeeping gene. (C) KB cells treated with MTX conjugate (640), alanine conjugate (188) or folate conjugate (356) polyplexes observed under the fluorescent microscope. The mitotic blockade that was induced by EG5 knockdown caused “aster formation” of nuclear DNA (arrows). DAPI stain. The scale bars represent 10 μm.](image-url)
It was further examined whether co-delivery of MTX conjugates and siEG5-Inf7 could potentiate the cytotoxic effect. As seen in Figure 3.1.12A, similar correlation between glutamylation degree and siEG5-induced cytotoxicity was found. Among the MTX conjugates, 640 (4E-MTX-Stp) and 641 (6E-MTX-Stp) polyplexes provided the highest potency to reduce cell viability of KB cells. As compared to free MTX or 356 siEG5-Inf7 polyplexes, MTX-conjugate siEG5-Inf7 polyplexes induced significantly superior cytotoxicity. Next, EG5-specific gene silencing was confirmed at mRNA level by qRT-PCR in KB cells (Figure 3.1.12B), where the tetraglutamyl variant 640 triggered very efficient downregulation of EG5 mRNA level, while it was significantly more potent than the folate-substituted control 356 (p< 0.01). Finally, functional EG5 gene silencing was confirmed via aster formation of nuclear DNA, where downregulation of EG5 induced a mitotic arrest in KB cells which had been transfected with 640 siEG5-Inf7 polyplexes or 356 siEG5-Inf7 polyplexes (Figure 3.1.12C). These results clearly indicated efficient silencing of EG5 expression at mRNA level, followed by mitotic blockade and finally cell death in KB cells. Moreover, it suggested that augmented tumor cell killing ability was mediated by a dual mechanism combining glutamyl-MTX oligomer with antitumoral siRNA.

**Figure 3.1.13.** MTT assay in MCF-7 cells treated with MTX or oligomers 356, 638, 639, 640, 641 at concentration between 1 - 10^4 nM for 48 h.

**Figure 3.1.14.** MTT assay in MCF-7 cells treated with MTX, oligomer or polyplexes (at 370 nM of siEG5-Inf7 or siCtrl-Inf7) for 24 h.
3.1.6 Prolonged intratumoral retention

The half-life of siRNA \textit{in vivo} is short, predominantly due to rapid elimination by renal filtration and biodegradation by RNases [73]. For example, our group previously reported that intratumoral retention of free siRNA lasts merely for 4 h [33]. From the previous work with analogous folate-PEG siRNA polyplexes, we know that these small (<10 nm) nanoparticles are stable in the blood upon systemic \textit{i.v.} injections, but rapidly eliminated \textit{via} kidneys, with recovery of intact polyplexes from urine (Figure S16 and S17 in Dohmen \textit{et al.} [23]). For this reason, both in the previous and the current study intratumoral injection (\textit{i.t.}) was the selected route of administration.

![Image](image.png)

\textbf{Figure 3.1.15.} Intratumoral distribution of siRNA polyplexes at N/P 16 in NMRI-nude mice bearing KB xenograft tumors determined by NIR fluorescence bioimaging. (A) Time-dependent retention of 50 μg of Cy7-labeled siRNA after intratumoral injection using MTX-conjugated oligomer 640 (upper panel), folate-conjugated control 356 (middle panel) or alanine substituted control 188 (lower panel) as carrier. (B) Harvested tumor samples at 168 h after injection of siRNA polyplexes. Experiments were performed in triplicates; a representative animal of each group is shown. The experiments were performed in collaboration with Eva Kessel (Dr. med. vet. study, Department of Pharmacy, Ludwig-Maximilians-Universität München).

To further examine whether MTX-conjugated oligomers could enhance the retention of siRNA within the tumor, Cy7-labeled siRNA formulated with 640 at N/P 16 was administered \textit{i.t.} to KB tumor-bearing mice. The biodistribution study with Cy7-labeled siRNA measured by near infrared (NIR) fluorescence imaging (Figure 3.1.15A) showed that the conjugation of MTX as targeting ligand significantly increased the tumoral retention of siRNA. Both targeted siRNA polyplexes (640 and 356) carried out remarkably longer retention (5 days) than that of untargeted 188 siRNA polyplexes by ~120 h. The MTX-based 640 siRNA polyplexes showed comparable retention as folate-based 356 siRNA polyplexes, and Cy7-labeled siRNA was still detectable 168 h after injection (Figure 3.1.15B). The biodistribution study provided evidence that these siRNA polyplexes were eliminated through renal clearance (Figure 3.1.16).
Results

Figure 3.1.16. Renal clearance of siRNA polyplexes in tumor-bearing NMRI-nude mice determined by NIR fluorescence bioimaging. After intratumoral injection using MTX-conjugated oligomer 640 (upper panel), folate-conjugated control 356 (middle panel) or alanine-substituted control 188 (lower panel) as carrier, Cy7-labeled siRNA was detected in the kidneys and the bladder. Experiments were performed in triplicates; a representative animal of each group is shown. The experiments were performed in collaboration with Eva Kessel (Dr. med. vet. study, Department of Pharmacy, Ludwig-Maximilians-Universität München).

3.1.7 Dual in vivo therapeutic effects by MTX-conjugated siRNA polyplexes

After confirming that FR-targeted siRNA polyplexes were well-retained in the tumor tissue, we further investigated the therapeutic potential of these polyplexes. For this, we formulated polyplexes of the tetruglutamyl-MTX conjugate 640 with siEG5-Inf7 or siCtrl-Inf7, free 640 (without siRNA), or polyplexes of the folate conjugate 356 with siEG5-Inf7, and administered these formulations i.t. in the KB tumor-bearing nude mice. In line with previous intratumoral administration studies, 50 µg of siRNA (diluted in 50 µL of HBG) was applied [33, 36]. To avoid unspecific immune reactions, we used 2’OMe-modified siRNA that is designed not to trigger toll-like receptor (TLR)-mediated immune responses [29, 30]. The post-treatment survival was recorded to provide Kaplan–Maier survival analysis. All animals treated with siRNA polyplexes showed significantly reduced tumor growth compared to untreated controls (Figure 3.1.17A). Importantly, combination treatment with 640 siEG5-Inf7 polyplexes nearly completely inhibited tumor growth 8 days after the treatment (Figure 3.1.17B), and all of these animals still showed no palpable or measurable tumor 17 days after the treatment (Figure 3.1.18). Encouragingly, three animals receiving 640 siEG5-Inf7 polyplexes have survived without recurrence until the study was ended (day 70) (Figure 3.1.17C). In addition, 640 siCtrl-Inf7 polyplexes induced superior effect over free 640 to inhibit tumor growth. With regard to antitumoral efficacy, the big difference between the EG5 and the control siRNA group 640 siCtrl-Inf7 polyplexes ruled out a significant contribution of immune reactions to the therapeutic effect. Nevertheless, 640 siCtrl-Inf7 polyplexes mediated higher antitumoral effect than that of free 640 (i.e. without siRNA complexation) to inhibit tumor growth. Possible explanations could be better intratumoral
Results
retention of multiple conjugated MTX ligands by 640 siRNA-Inf7 nanoparticle formation, or improved cytosolic delivery of the MTX molecules facilitated by the endosomolytic Inf7 peptide. Interestingly, 356 siEG5-Inf7 polyplexes resulted in comparable effect in terms of tumor suppression and survival time as free 640 (30.8 ± 2.3 days vs. 29.7 ± 2.4 days).

Figure 3.1.17. In vivo validation of augmented antitumoral effect by MTX-conjugated siRNA polyplexes. (A) Therapeutic efficacy of MTX-conjugated 640 polyplexes (with siEG5-Inf7 or siCtrl-Inf7), free oligomer 640 (without siRNA), or folate-conjugated 356 siEG5-Inf7 polyplexes in KB xenograft (n = 6 per group). The insert shows a comparison of the tumor volume in different groups 5 days after the last treatment (day 22). (B) Representative KB tumor lesions from the cohorts in (A) on day 25. (C) The Kaplan–Maier survival curve of the animals treated with indicated formulations. In the animals receiving 640 siEG5-Inf7 polyplexes, tumors largely disappeared by day 22, and in 3 animals no recurrence was observed until the end of the study (day 70). The experiments were performed in collaboration with Eva Kessel (Dr. med. vet. study, Department of Pharmacy, Ludwig-Maximilians-Universität München).
Results

Figure 3.1.18. KB tumor-bearing animals were administered *i.t.* with 640 siRNA polyplexes (with siEG5-Inf7 or siCtrl-Inf7, and the tumor sizes were measured 1 day (day 18) or 17 days (day 30) after the last treatment. No palpable or measurable tumor was found on day 30 in the animals treated with 640 siEG5-Inf7. The experiments were performed in collaboration with Eva Kessel (Dr. med. vet., Department of Pharmacy, Ludwig-Maximilians-Universität München).

In the tumors treated with 640 siEG5-Inf7 polyplexes or 356 siEG5-Inf7 polyplexes, necrotic tumor tissue accompanied by an active healing process was observed. In general, scars started to fade and thin out gradually after the treatments (Figure 3.1.19). At the same time, equivalent intratumoral dosages of free MTX did not reduce tumor growth (Figure 3.1.20). Moreover, monitoring of body weights demonstrated that the treatment was well tolerated (Figure 3.1.21). Temporary stagnation of body weight (days 11–18) in the treated animals was possibly due to tumor necrosis-associated discomfort, and a rapid gain of weight after the treatments was noted. These results suggest that the tetraglutamyl-MTX ligand provides tumor-suppressive potential, and effective EG5 silencing by FR-targeted polyplexes represents a potential strategy for tumor treatment, which can be further combined with MTX-conjugated 640 for improved therapeutic efficacy.

Figure 3.1.19. The necrotic tumor tissue followed by an active healing process was found in the KB tumor-bearing animals treated with 640 siEG5-Inf7 polyplexes or 356 siEG5-Inf7 polyplexes. The healing process could be different for different individuals, while the wounds were eventually repaired as shown in the representative pictures from the animals treated with 640 siEG5-Inf7 polyplexes.
Results

Figure 3.1.20. Tumor growth curve after the intratumoral injection of free MTX or glutamyl-MTX conjugate 640 in KB xenografts (n = 6 per group). (A) Therapeutic efficacy of free MTX or free oligomer 640. (B) The Kaplan-Maier survival curve of the animals receiving indicated formulations. The experiments were performed in collaboration with Eva Kessel (Dr. med. vet. study, Department of Pharmacy, Ludwig-Maximilians-Universität München).

Figure 3.1.21. The body weights of the animals receiving different formulations were monitored on a daily basis until the animals were sacrificed. The experiments were performed in collaboration with Eva Kessel (Dr. med. vet. study, Department of Pharmacy, Ludwig-Maximilians-Universität München).
3.2 Targeted combinatorial polyplexes (TCPs)

3.2.1 Formation of TCPs

This chapter has been partly adapted from:

Based on previous studies, four oligomers were selected from the library to generate novel combinatorial formulations for targeted siRNA delivery (Scheme 3.2). This work was performed in collaboration with Dr. Dongsheng He (PhD study, Department of Pharmacy, Ludwig-Maximilians-Universität München). Three-arm Stp oligomers 386 and 689, were chosen for their strong siRNA binding ability, which provide a highly stable cationic core to compact siRNA [35, 36, 74]. Moreover, PEG-folate-conjugated Sph oligomers (4-arm) 709 and (2-arm) 717, were used for FR targeting and surface shielding [75]. Here we combined these two types of oligomers, in order to optimize the siRNA polyplexes by co-formulation. All oligomers contain terminal cysteines with free thiol groups for subsequent disulfide formation within siRNA polyplexes. As standard disulfide formation by air oxidation has been found to be a rather slow and incomplete process, we intended to make this step faster and more specific. Therefore, we activated the thiol groups of oligomer #1 with 5,5’-dithio-bis(2-nitrobenzoic acid) (DTNB) to produce TNB-modified oligomer (Figure 3.2.1A). The TNB-modified oligomer formed a binary siRNA polyplex with siRNA, and in the following incubation with the unmodified thiol-oligomer #2 it would undergo a fast uni-directional coupling through disulfide formation with the free thiol groups of thiol-oligomer #2 in three dimensions, resulting in hypothetic nanogel structures (Scheme 3.2). The combination of siRNA with both oligomers thus generated targeted combinatorial polyplexes (TCPs), which were composed of compact cationic core for siRNA binding, well-shielded PEG layer and folates as targeting ligands (Figure 3.2.1B). TCPs were optimized by testing different TNB-modified oligomers #1 / unmodified thiol oligomers #2 at various molar ratios, and by evaluating three different siRNA / oligomer #1 / oligomer #2 mixing sequences. Preliminary gene silencing experiments (Figure 3.2.2) demonstrated that tested mixing sequences presented similar efficiencies as the first alternative (pre-incubated siRNA with the TNB-modified oligomer #1, followed by disulfide exchange reaction with thiol oligomer #2). For practical reasons, all further testing was performed with this mixing sequence.
Results

Figure 3.2.1. Targeted combinatorial polyplexes (TCPs) with folate ligand for siRNA delivery. (A) TNB-modified oligomer #1 was obtained by reacting the solid-phase derived thiol precursor oligomer #1 with 10 eq of DTNB for 2 h at room temperature. The incubation of TNB-modified oligomer #1 with siRNA formed a binary polyplex. Addition of thiol-oligomer #2 resulted in fast uni-directional coupling of TNB-modified oligomer #1 through disulfide formation with the free thiol groups of #2. In this way siRNA, TNB-modified oligomer and unmodified thiol-oligomer were formulated to produce a TCP. (B) Schematic presentation of key elements of a TCP. Endosomolytic Inf7 peptide was conjugated to siRNA for enhanced endosomal escape [33].

As a result, four combinatorial formulations, TCP1, TCP2, TCP3 and TCP4, were developed (Scheme 3.2). TCP1 and TCP3 shared the similar combined structure of 386 + 709 (Scheme 3.2 top); TCP2 and TCP4 shared the similar combined structure of 689 + 717 (Scheme 3.2 bottom). Differences rose from the alternative TNB-activations of oligomers. After systematic screening and evaluating different molar ratios of oligomers (Tables S1-S4 in [76]), equal molar (1:1) oligomer ratios at N/P 16 was determined as most useful for the subsequent experiments.
Results

<table>
<thead>
<tr>
<th>TCP1</th>
<th>TCP3</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>TNB-Oligomer #1</strong></td>
<td><strong>TNB-Oligomer #1</strong></td>
</tr>
<tr>
<td>(4-arm 873) K-(PEG_{24}-Folate)-K-[K-(Sph_{4}-C-TNB)]_{2}</td>
<td>(3-arm 769) TNB-C-Stp_{3}-K-(Stp_{3}-C-TNB)]_{2}</td>
</tr>
<tr>
<td>(N/P 11.2)</td>
<td>(N/P 4.8)</td>
</tr>
<tr>
<td><strong>Thiol-Oligomer #2</strong></td>
<td><strong>Thiol-Oligomer #2</strong></td>
</tr>
<tr>
<td>(3-arm 386) C-Stp_{3}-K-(Stp_{3}-C)_{2}</td>
<td>(4-arm 709) K-(PEG_{24}-Folate)-K-[K-(Sph_{4}-C)]_{2}</td>
</tr>
<tr>
<td>(N/P 4.8)</td>
<td>(N/P 11.2)</td>
</tr>
</tbody>
</table>

**Combined Structure**

![Combined Structure](image)

**Scheme 3.2.** Targeted combinatorial polyplex (TCP) formulations. siRNA was co-formulated with TNB-modified oligomers and unmodified thiol-oligomers at various molar ratios to form the TCP carriers. In most experiments polyplexes were formed at N/P 16 using an equal molar oligomer ratio of 1:1; for these conditions the individual N/P ratio of each oligomer is presented. The oligomer sequences are indicated (left to right) from C- to N- terminus. C: cysteine; H: histidine; K: lysine; Y: tyrosine; S-S: disulfide crosslinking; PEG_{24}: polyethylene glycol; TNB: 5-thio-2-nitrobenzoic acid; Stp: succinoyl-tetraethylene pentamine; Sph: succinoyl-pentaethylene hexamine. K- and K-[ refer to branchings by α- and ε-amino modification of lysines. x: hypothetic nanogel structures resulting from disulfide crosslinking in three dimensions within the TCP.
3.2.2 Physicochemical characterizations

Formulating TCPs (Scheme 3.2) at N/P 16, we measured the particle sizes by dynamic laser-light scattering (DLS) based on different molar ratios of [TNB-modified oligomer #1 / unmodified thiol-oligomer #2]. At the ratio of 1:1, the sizes of the two 386 + 709 formulations, TCP1 and TCP3, are 104 nm and 209 nm, respectively, whereas the two 689 + 717 formulations, TCP2 and TCP4, have a larger size of ~ 400 nm (Table 3.2.1). To examine the effect of PEG shielding on the surface charge of TCPs, zeta potentials of siRNA polyplexes at N/P 16 were measured (Table 3.2.1). For TCP1, TCP2 and TCP4, the zeta potential values were reduced from approximately ≥ +20 mV [35] to values around + 8-9 mV. It is interesting that TCP3, comprising the same oligomers by a different activation scheme, displayed a highly positive zeta potential of +24 mV.

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Size (nm)</th>
<th>Pdl</th>
<th>Zeta potential (mV)</th>
</tr>
</thead>
<tbody>
<tr>
<td>TCP1</td>
<td>103.5 ± 0.8</td>
<td>0.239 ± 0.026</td>
<td>9.1 ± 0.2</td>
</tr>
<tr>
<td>TCP2</td>
<td>429.4 ± 53</td>
<td>0.213 ± 0.017</td>
<td>7.93 ± 0.21</td>
</tr>
<tr>
<td>TCP3</td>
<td>208.8 ± 3.4</td>
<td>0.267 ± 0.011</td>
<td>24.3 ± 0.3</td>
</tr>
<tr>
<td>TCP4</td>
<td>398.3 ± 63.5</td>
<td>0.229 ± 0.017</td>
<td>8.1 ± 0.05</td>
</tr>
</tbody>
</table>

Table 3.2.1. Size and zeta potential of TCPs at N/P 16 measured by DLS measurements. [TNB-modified oligomer / unmodified thiol-oligomer] molar ratio = 1:1. The experiments were performed by Dr. Dongsheng He (PhD study, Department of Pharmacy, Ludwig-Maximilians-Universität München).

To study the morphology of these formulations, we carried out transmission electron microscopy (TEM) measurements. As shown in Figure 3.2.3A, these images indicated the formation of homogeneous spherical nanoparticles with sizes in a range consistent with the DLS measurements. No aggregates were observed for these siRNA polyplexes. Moreover, to validate the siRNA binding activity of TCPs, we analyzed the siRNA polyplex formation by agarose gel shift assay (Figure S2-5 in [76]). In general, when increasing the fraction of 3-arm Stp oligomers in TCP formulations, the siRNA binding was significantly increased. Apparently the 3-arm Stp oligomers
were essential for compaction and stability of siRNA polyplexes. At the molar ratio of 1:1, all TCP formulations exhibited complete siRNA binding at N/P 16 (Figure 3.2.32B).

Figure 3.2.3. Physicochemical assessments of TCPs. (A) TEM images of TCPs at N/P 16. (B) siRNA binding of TCPs at N/P 16 determined by agarose gel shift assay. Free siRNA and folate-linked PEGylated oligomer 356 [33] were used as controls.
3.2.3 Receptor-mediated uptake of TCPs

As folate retains high affinity for FR following derivatization via one of its two carboxylate groups [77], folate conjugation presents an advantageous strategy for FR-targeted drug delivery. To validate targeting capacity of the folate-linked TCPs, fluorescent Cy5-labeled siRNA was used to study the cellular internalization profile by flow cytometry. To investigate selective targeting ability of TCPs against FR, FR-rich cancer cell lines (murine lymphocytic leukemia L1210 cells, murine lung carcinoma M109 cells and human cervix carcinoma KB cells) and FR-deficient human mammary adenocarcinoma MCF-7 cells [45, 67, 78-80] were applied for the following experiments.

Figure 3.2.4. Folate receptor (FR)-mediated uptake and intracellular distribution of TCPs. (A) The cellular internalization capacity of TCPs was evaluated by comparing the cellular internalization of siRNA polyplexes into FR-overexpressing M109 and L1210 vs. FR-deficient MCF-7 cells. siRNA polyplexes were prepared at N/P 16 with Cy5-labeled siRNA. The cells were incubated with siRNA polyplexes at 37 °C for 4 h before flow cytometric measurements. The amount of Cy5-positive cells was analyzed through excitation of the dye at 635 nm and detection of emission at 665/20 nm. (B-G) Immunoelectronmicroscopy of FR-mediated endocytic pathway of TCP1 in FR-overexpressing KB cells. TCP1 was formed at N/P 16 with biotinylated-siRNA tagged with 10 nm neutravidin-gold particles. FR was visualized with anti-FR-α antibodies and Protein-G coupled to 6 nm gold particles. (B) Association of siRNA polyplexes with the cell surface after incubation of cells with siRNA polyplexes for 15 min. (C) The colocalization of siRNA polyplexes with FR in membrane invagination after incubation for 15 min. (D) The FR localizing in close proximity to siRNA polyplexes in membrane invagination indicated by yellow arrowheads or dots in higher-magnification image and the scheme of (C), respectively. (E) Colocalization of FR (yellow dots) with siRNA polyplexes inside endosomal vesicles after incubation for 1 h. (F) The higher-magnification image of (E) indicating FR by yellow arrowheads. (G) Endosomal structures with disrupted membrane, indicating endosomal escape of siRNA molecules after incubation for 4 h. The experiments were performed in collaboration with Dr. Kärt Padari (Institute of Molecular and Cell Biology, University of Tartu).
The cells were treated with TCPs at N/P 16 for 4 h at 37 °C, and then uptake of siRNA polyplexes was analyzed by flow cytometry (Figure 3.2.4A). Generally, all the TCP formulations exhibited strong cellular internalization in FR-rich cells. The uptake levels for TCPs in L1210 cells were similar (87-95% positive cells), which were higher than the levels in M109 cells (73-86% positive cells). In contrast, after transfecting FR-deficient MCF-7 cells with TCPs, the uptake levels were very low (5-9%). Hence, the cellular uptake studies demonstrated that folate-conjugated TCP formulations were taken up into cells in a receptor-specific fashion, based on the observations that siRNA polyplexes efficiently bound to FR-expressing L1210 and M109 cells, and the uptake of TCPs diminished in FR-negative MCF-7 cells. To further confirm the involvement of FR in the cellular uptake of TCPs, and to gain more detailed insight into how these polyplexes associate with receptors and how they are endocytosed by cells, immuno-TEM was used [81]. These studies were performed during a research visit at Institute of Molecular and Cell Biology, University of Tartu. For detecting the colocalization of TCPs and FR, we used different sizes of gold particles for immuno-labeling. The primary antibodies against FR were visualized with Protein G-gold conjugates (6 nm in diameter), whereas biotinylated siRNA was labeled with neutravidin-gold conjugates (10 nm in diameter). Namely, 6 nm-gold probe for detecting FR and 10 nm gold tag for detecting siRNA polyplexes should be distinguishable in cells by TEM at ultrastructural scale. To examine the internalization process of TCPs starting from their initial binding to the cell surface and subsequent intracellular pathway, FR-positive KB cells were incubated with 10 nm gold label-containing TCP1 for 15 min, 1 h and 4 h. After incubation for 15 min, siRNA polyplexes were detected as electron dense particles associated with the cell surface (Figure 3.2.4B) and induced invaginations in the plasma membrane of KB cells (Figure 3.2.4C). As illustrated in the higher-magnification image we observed the receptors (indicated by arrowheads in Figure 3.2.4D) were in close proximity to siRNA polyplexes in endosomal invaginations. At 1 h, inside cells, most of siRNA polyplexes were entrapped in endosomal structures, where they formed large dense TCP1 clusters and some retained association with the membrane of endosomal vesicles (Figure 3.2.4E). Although the polyplexes localized in densely packed clusters in the endosomal structures, we were able to distinguish some smaller gold particles representing the FR that had associated with TCPs (arrowheads in Figure 3.2.4F). In addition, a small fraction of the endosomal structures had lost the intactness of its limiting membrane (Figure 3.2.4G) already within 4 h and siRNA molecules had escaped from the ruptured vesicles, and infrequently, single 10 nm gold particles denoting TCPs were detected diffusely in cytosol. In contrast, non-targeted siRNA polyplexes were very rarely detected in KB cells or associated with their surface.
3.2.4 Gene silencing efficiency of TCPs

After showing that the folate-conjugated TCPs utilized FR for cellular association and intracellular delivery of siRNA, next their ability to induce target gene silencing was evaluated. In order to validate this, siGFP or siCtrl was used to transfect the KB/eGFPLuc cells, and gene silencing efficiency of siRNA polyplexes was evaluated via luciferase activity by luminometric analysis. Former studies of our group indicated that PEGylated siRNA polyplexes, similar as several other PEG-shielded polyplexes [82], face the problem of endosomal entrapment into the cytosol [33]. For this reason, the synthetic peptide Inf7, previously designed as pH-specific analog of the influenza virus hemagglutinin subunit 2 (HA2) N-terminal fusion sequence [72, 83, 84], was covalently coupled to siRNA as endosomolytic agent [33, 53, 85]. In this assay, we sought to compare the transfection efficiency of TCPs with the previously published 356 [33]. As shown in Figure 3.2.5, all the TCP formulations containing Inf7-modified siGFP (siGFP-Inf7) at N/P 16 mediated significant gene silencing efficiency in KB/eGFPLuc cells, as 75-94% of luciferase activity was suppressed. Among these TCP formulations, TCP1 exhibited the most potent gene silencing activity (94%), which is comparable to 356 nanoplexes (90%) and superior to the rest of TCPs. In contrast, in the cells treated with unmodified siGFP polyplexes, the silencing effect was significantly decreased (45-63% for TCPs and 35% for 356), further highlighting that Inf7 peptide is necessary for sufficient release of siRNA into cytosol, as reported earlier [33, 53, 85].

Figure 3.2.5. Gene silencing efficiency of TCPs in KB cells expressing eGFPLuc fusion protein (KB/eGFPLuc cells). The siRNA polyplexes were prepared at N/P 16 with different siRNA sequences: eGFP-targeted siRNA (siGFP), control siRNA (siCtrl), or siRNA chemically linked with the endosomolytic peptide Inf7 (siGFP-Inf7 or siCtrl-Inf7).
3.2.5 Tumor-specific toxicity mediated by EG5 gene silencing

As aforementioned, TCPs facilitated functional gene silencing with Inf7-modified siRNA \textit{in vitro}, we next sought to investigate, whether we could mediate tumor-specific cytotoxicity by using antitumoral siRNA. For this purpose, we exploited siRNA against EG5 (siEG5-Inf7) that corresponds to a sequence of the EG5 coding region conserved between human and mouse, which is able to block the formation of bipolar mitotic spindles, causing cell-cycle arrest and induction of apoptosis [27]. After incubating the cells with siEG5-Inf7 TCPs, MTT assay revealed that all the TCP formulations were cytotoxic to the FR-expressing M109 cells (Figure 3.2.6A). TCP1 and TCP2 mediated the higher cell killing (90%; 85%) than TCP3, TCP4 or the folate-conjugated 356. Besides, siCtrl-Inf7 TCPs did not affect cell viability of M109 cells. Meanwhile, in FR-negative MCF-7 cells, there’s no similar cytotoxic effect induced by TCPs (Figure 3.2.6B). Moreover, functional EG5 gene silencing was confirmed \textit{via} aster formation of nuclear DNA, where downregulation of EG5 induced a mitotic arrest in siEG5-Inf7-treated M109 cells. After incubation with siEG5-Inf7 polyplexes, Figure 3.2.6C showed the typical mitotic figures in dividing cells by DAPI staining. No aster formation could be observed after application of control siRNA polyplexes. Further examination of EG5-specific gene silencing at mRNA level was performed by qRT-PCR in FR-expressing L1210 cells. Figure 3.2.6D revealed that all the siEG5-Inf7 TCPs triggered very efficient downregulation of EG5 Mrna levels, while TCP1 was significantly more potent than the rest of formulations. In the siCtrl-Inf7-treated cells, the mRNA expression levels were similar to untreated cells, which also reflected that there was no off-target effect by TCPs. Therefore, these results clearly supported that folate-conjugated TCPs enabled efficient silencing of EG5 gene expression at mRNA level, followed by mitotic blockade and finally cell death in FR-positive cells.

\textbf{Figure 3.2.6.} Cell transfections with TCPs containing Inf7 peptide-modified EG5-targeted siRNA (siEG5-Inf7) or control siRNA (siCtrl-Inf7) at N/P 16. MTT assay in (A) FR-positive M109 cells and (B) FR-negative MCF-7 cells after transfection with TCPs. (C) M109 cells treated with TCPs visualized by fluorescence microscopy after DAPI staining of DNA. The mitotic blockade that was induced by EG5 knockdown caused "aster formation" of nuclear DNA (arrowheads). The scale bars represent 10 \( \mu \)m. (D) mRNA level of EG5 gene measured by qRT-PCR after transfection of TCPs in FR-positive L1210 cells. GAPDH was used as housekeeping gene.
3.2.6 **Distribution of TCPs in tumor-bearing mice upon systemic administration**

Upon systemic administration, unmodified siRNA is easily eliminated via renal clearance because of the small size, thus the half-life of siRNA *in vivo* is very short (few minutes) [86]. Moreover, it can also be enzymatically degraded by endogenous RNases with a serum half-time ranges from several minutes to 1 h [87]. To investigate whether TCPs could improve the distribution profile of siRNA, TCP1, the most potent formulation *in vitro* with favorable size and surface charge, was selected for the further *in vivo* studies. The two single oligomer components of TCP1, *i.e.* 3-arm Stp-based oligomer 386 and DTNB-modified 4-arm PEGylated folate-equipped Sph oligomer 873, were used for comparison. FR-expressing L1210 tumor cells were implanted subcutaneously in nude mice. We formulated different Cy7-labeled siRNA (50 µg of siRNA) polyplexes at N/P 16, and administered these siRNA polyplexes intravenously (*i.v.*). The biodistribution of Cy7-labeled siRNA measured by near infrared (NIR) fluorescence imaging (Figure 3.2.7A) showed that for TCP1 the systemic distribution of Cy7 signal lasted more than 1 h, and in the meanwhile the tumoral retention of siRNA was observed. In case of the non-targeted 3-arm Stp-based oligomer, Cy7 signal disappeared after ~30 min, and siRNA barely reached the tumor site.

**Figure 3.2.7.** Biodistribution of siRNA polyplexes at N/P 16 in NMRI-nude mice bearing L1210 tumors determined by NIR fluorescence bioimaging. (A) Time-dependent retention of 50 µg of Cy7-labeled siRNA after *i.v.* injection using TCP1, 3-arm Stp oligomer 386, DTNB-modified PEGylated folate-conjugated 4-arm Sph oligomer 873 as carriers. Lateral views of animals were shown to present the tumor sites. (B) Tumors harvested 15 min, 1 h or 4 h after injection of siRNA polyplexes. (C) Distribution and elimination of TCP1 over 24 h. (D) Tumors and organs of TCP1-treated animals harvested 1 h or 24 h after injection of siRNA polyplexes. Experiments were performed with 3-4 animals per group; a representative animal of each group is shown. The experiments were in collaboration with Eva Kessel (Dr. med. vet. study, Department of Pharmacy, Ludwig-Maximilians-Universität München).

Additionally, DTNB-modified 4-arm folate conjugate exhibited the first evidence for the tumoral retention of siRNA within 15 min, and the systemic distribution was longer than 3-arm Stp-based oligomer. As control, free siRNA was rapidly filtered by kidneys within 30 min. Notably, Cy7 siRNA was detectable in harvested tumors only from TCP1-treated animals at 1 h, while there was no Cy7 signal in the rest of groups (Figure 3.2.7B). In TCP1-treated animals, the tumor presented the second highest remaining Cy7 signal after the kidneys at 1 h, and both *in vivo* and
Results

ex vivo imaging reflected that siRNA was eliminated through renal clearance within 24 h (Figure 3.2.7C and D).

3.2.7 Tumor-targeted EG5 gene silencing in vivo

After confirming that FR-specific TCP1 successfully delivered siRNA in the tumor tissue via systemic administration, we sought to validate the functional gene silencing of TCP1 in vivo. For this purpose, we formulated TCP1 with siEG5-Inf7 or siCtrl-Inf7 (50 µg of siRNA) at N/P 16, and administered these siRNA polyplexes i.v. in the L1210 tumor-bearing mice twice. 24 h after the last treatment, the tumors were harvested. RNA was isolated from tumor tissues, and mRNA expression levels of EG5 gene were evaluated by qRT-PCR. Compared to untreated controls, the siEG5-Inf7 TCP1 reduced the EG5 gene expression by 46%. Importantly, the siCtrl-Inf7 TCP1 showed negligible effects on EG5 mRNA level as compared with untreated tumors (Figure 3.2.8A).

![Figure 3.2.8](image)

**Figure 3.2.8.** Tumor-targeted gene silencing efficiency of TCP1 in L1210 tumor-bearing mice. (A) mRNA level of EG5 gene after two-fold i.v. injection of TCP1 with 50 µg of siEG5-Inf7 or siCtrl-Inf7 at N/P 16. (B) Body weight development over treatment period. The i.v. injections were performed at day 13 and 14 as indicated by arrows. The body weight curves of TCP1-treated animals were compared to that of untreated animals over the same time after tumor inoculation. Experiments were performed with 5 animals per group. The experiments were in collaboration with Eva Kessel (Dr. med. vet. study, Department of Pharmacy, Ludwig-Maximilians-Universität München).

Systemic circulation of siRNA polyplexes might also lead to enhanced exposure to non-target tissues which might cause side effects; we thus monitored the body weights and carried out blood biochemistry examination as preliminary evaluation of potential side effects. As seen in Figure 3.2.8B, the body weight curves indicate that the treatments were well-tolerated compared to untreated controls. We took blood samples 24 h after the treatments to determine the four clinical biochemistry parameters (ALT, AST, BUN and creatinine). Elevated liver enzymes (ALT and AST) would indicate formulation-related liver damage or acute hepatitis, while increased BUN or creatinine would be related to renal malfunctions. As presented in Table 3.2.2, in the treatment groups, liver enzymes were almost equivalent to the untreated control group. In terms of BUN, there was no significant elevation, either. Creatinine showed an elevation for TCP1 with siEG5-
Inf7 treated animals compared to untreated controls, but still these serum values were lower than the reference range of female NMRI-nu/nu mice at the same age (data sheet of NMRI-nu/nu, Janvier Labs). Therefore, TCP1 exhibited siRNA delivery into the tumor and resulted in EG5 gene silencing at mRNA level in the absence of detectable adverse effects.

**Table 3.2.2.** Clinical biochemistry parameters (ALT, AST, BUN and creatinine). Plasma was obtained from the treated animals 24 h after the second injection (n = 5) compared to untreated tumor-bearing mice (n = 3) that were euthanized on the same day.

<table>
<thead>
<tr>
<th></th>
<th>ALT (U/L)</th>
<th>AST (U/L)</th>
<th>Creatinine (mg/dL)</th>
<th>BUN (mg/dL)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>TCP1 + siEG5-Inf7</strong></td>
<td>34 ± 15</td>
<td>80 ± 28</td>
<td>0.1 ± 0.01*</td>
<td>43 ± 13</td>
</tr>
<tr>
<td><strong>TCP1 + siCtrl-Inf7</strong></td>
<td>39 ± 2</td>
<td>115 ± 36</td>
<td>0.08 ± 0.02</td>
<td>39 ± 6</td>
</tr>
<tr>
<td><strong>Untreated</strong></td>
<td>46 ± 15</td>
<td>113 ± 23</td>
<td>0.07 ± 0.01</td>
<td>38 ± 7</td>
</tr>
</tbody>
</table>

* significant difference between untreated control and TCP1 + siEG5-Inf7 treated group.
3.3 Targeted lipopolyplexes (TLPs)

3.3.1 Formation of TLPs

To prepare targeted lipopolyplexes (TLPs) for siRNA delivery, four oligomers from a recently established library of sequence-defined oligomers were chosen (Figure 3.3.1A) [33, 35-37]. Among these, the PEG-folate-conjugated Stp oligomer (356) formed neutralized siRNA nanoplexes (TEM images shown in Figure 3.3.1B) but with moderate siRNA binding ability (Figure 3.3.2) [33]. At the same time, fatty acid-modified 454 siRNA polyplexes formed positively charged particles with diameter of 100-130 nm (TEM images were shown in Figure 3.3.1B) with very prominent siRNA binding ability (Figure 3.3.3) [37, 59]. Thus, to optimize the physicochemical properties of siRNA polyplexes, 356 was combined with 454 by different [targeted PEG oligomer / lipo-oligomer] molar ratios to formulate siRNA as TLP1 formulation. For that both oligomers contain terminal cysteines, crosslinkage through disulfide formation is assumed to glue together all three components.

Figure 3.3.1. Targeted lipopolyplexes (TLPs) for siRNA delivery. (A) Structures of targeted PEGylated oligomer (356) and lipo-oligomers (454, 49 and 229). C: cysteine; K: lysine; Y: tyrosine; PEG: polyethylene glycol; Stp: succinoyl-tetraethylene pentamine; OleA: oleic acid; LinA: linolic acid; K and K refer to branchings by α- and ε-amino modification of lysines. Illustrations and TEM micrographs of (B) targeted PEGylated polyplexes (by folate-conjugated 356 and siRNA), lipopolyplexes (by oleic acid-modified 454 and siRNA) and (C) TLPs (by co-formulations of targeted PEGylated oligomer, lipo-oligomer and siRNA). TLP1: 356 + 454; TLP2: 356 + 49; TLP3: 356 + 229. The TEM imaging was performed in collaboration with Susanne Kempter (Faculty of Physics, Ludwig-Maximilians-Universität München).
Figure 3.3.2. siRNA binding of targeted PEG oligomer (356) at N/P 16 determined by agarose gel shift assay. Free siRNA was used as control.

Figure 3.3.3. siRNA binding of lipo-oligomers (49, 229, 454) at N/P 16 determined by agarose gel shift assay. Free siRNA was used as control.

Table 3.3.1. TLP Formulations

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Targeted PEG Oligomer</th>
<th>Lipo-Oligomer</th>
</tr>
</thead>
<tbody>
<tr>
<td>TLP1</td>
<td>Folate-PEG24-K(Stp4-C)2 (356)</td>
<td>C-Y2-Stp2-{[(OleA)2-K]K-Stp2-Y3-C (454)}</td>
</tr>
<tr>
<td>TLP2</td>
<td></td>
<td>C-Stp2-{[(OleA)2-K]K-Stp2-C (49)}</td>
</tr>
<tr>
<td>TLP3</td>
<td>(LinA)2-K-C-Stp3-C (229)</td>
<td></td>
</tr>
</tbody>
</table>

*The sequence implies from C- terminal to N- terminal. C: cysteine; K: lysine; Y: tyrosine; PEG: polyethylene glycol; Stp: succinoyl-tetraethylene pentamine; OleA: oleic acid; LinA: linolic acid; K[ and K{ refer to branchings by α- and ε-amino modification of lysines.

Moreover, based on this strategy, as shown in Table 3.3.1 and Figure 3.3.1C, lipo-oligomer with different motifs such as oleic acid lipo-oligomer (49) or linolic acid lipo-oligomer (229) was combined with targeted PEGylated oligomer (356) to prepare TLP2 and TLP3, respectively.

As measured by dynamic light scattering (DLS) (Table 3.3.2), the surface charge of TLP1 at N/P 16 was dramatically shifted from +16.4 mV (at the ratio of 0%:100% lipo-oligomer) to +2.5 mV (at the ratio of 10%:90%) by addition of PEGylated 356. At the ratio of 30%:70%, TLP1 presented neutralized zeta potential value and diameter of ~127 nm. Similarly, TLP2 displayed zeta potential value of +0.1 mV and size of ~90 nm (Table 3.3.3) at the ratio of 30%:70%, while TLP3 exhibited shielded surface charge (+9.2 mV) and size of ~198 nm at the ratio of 20%:80% (Table 3.3.4). Consistent among the TLPs, the morphology of formulations assessed by TEM indicated the TLPs were homogeneous spherical nanoparticles with size in a range similar to the DLS measurements (Figure 3.3.1C). Additionally, when the ratio approached 50%:50%, probably the hydrophilicity/hydrophobicity balance between two classes of oligomers was unstable, the increased particle heterogeneity and even agglomeration were observed from the DLS results.
To evaluate the siRNA binding ability of TLPs at different mixing ratios, we performed gel shift assays (Figure 3.3.4-3.3.6). When the fraction of lipo-oligomers was increased in the TLPs, the siRNA binding was greatly potentiated. Notably, complete siRNA binding was observed between the ratio of 10%:90% and 30%:70% for TLPs. Compared to polyplexes, the results indicated that the presence of the lipo-oligomer in TLP formulations resulted in much improved siRNA binding efficiency, while tyrosine-modified in the TLP1 had highest capacity from these formulations to stabilize the siRNA polyplexes [37]. In conclusion, by co-formulating two functional oligomers, the successful modification of polyplexes was accompanied by distinct changes in the physicochemical properties with tunable sizes, surface shielding and improved siRNA binding. According to these results, the molar ratios of two oligomers for TLPs were optimized (30%:70% for TLP1 and TLP2; 20%:80% for TLP3) for the following in vitro and in vivo studies.

Table 3.3.2. Size and zeta potential of TLP1 at N/P 16 by DLS measurements. Folate-PEG24-K(Stp4-C)2 (356) as targeted PEG oligomer and C-Y3-Stp2-[(OleA)2-K]K-Stp2-Y3-C (454) as lipo-oligomer were co-formulated according to different molar ratios to form siRNA polyplexes.

<table>
<thead>
<tr>
<th>[Targeted PEG Oligomer / Lipo-oligomer] Molar Ratio</th>
<th>Targeted PEG Oligomer</th>
<th>Lipo-oligomer</th>
<th>Individual N/P Ratios</th>
<th>Size (nm)</th>
<th>PdI</th>
<th>Zeta Potential (mV)</th>
</tr>
</thead>
<tbody>
<tr>
<td>- 100%</td>
<td>-</td>
<td>16</td>
<td>114.6±0.92</td>
<td>0.201±0.003</td>
<td>16.4±0.09</td>
<td></td>
</tr>
<tr>
<td>10% 90%</td>
<td>2.8</td>
<td>13.2</td>
<td>130.6±0.56</td>
<td>0.137±0.004</td>
<td>2.5±0.24</td>
<td></td>
</tr>
<tr>
<td>20% 80%</td>
<td>5.2</td>
<td>10.8</td>
<td>128.7±0.63</td>
<td>0.159±0.004</td>
<td>2±0.17</td>
<td></td>
</tr>
<tr>
<td>30% 70%</td>
<td>7.2</td>
<td>8.8</td>
<td>126.6±2.17</td>
<td>0.121±0.007</td>
<td>-0.1±0.18</td>
<td></td>
</tr>
<tr>
<td>40% 60%</td>
<td>9</td>
<td>7</td>
<td>1143±205.3</td>
<td>0.96±0.057</td>
<td>0.7±0.07</td>
<td></td>
</tr>
<tr>
<td>50% 50%</td>
<td>10.5</td>
<td>5.5</td>
<td>674±196.9</td>
<td>0.693±0.222</td>
<td>3.7±0.14</td>
<td></td>
</tr>
<tr>
<td>60% 40%</td>
<td>11.9</td>
<td>4.1</td>
<td>402±130.6</td>
<td>0.557±0.194</td>
<td>0.2±0.2</td>
<td></td>
</tr>
<tr>
<td>70% 30%</td>
<td>13.1</td>
<td>2.9</td>
<td>340±4.5</td>
<td>0.313±0.01</td>
<td>2.6±0.9</td>
<td></td>
</tr>
<tr>
<td>80% 20%</td>
<td>14.2</td>
<td>1.8</td>
<td>296±30.8</td>
<td>0.323±0.03</td>
<td>0.03±0.02</td>
<td></td>
</tr>
<tr>
<td>90% 10%</td>
<td>15.1</td>
<td>0.9</td>
<td>295±21.7</td>
<td>0.333±0.009</td>
<td>1.5±0.17</td>
<td></td>
</tr>
</tbody>
</table>
### Table 3.3.3. Size and zeta potential of TLP2 at N/P 16 by DLS measurements.

<table>
<thead>
<tr>
<th>Targeted PEG Oligomer / Lipo-oligomer Molar Ratio</th>
<th>Individual N/P Ratios</th>
<th>Size (nm)</th>
<th>PdI</th>
<th>Zeta Potential (mV)</th>
</tr>
</thead>
<tbody>
<tr>
<td>-</td>
<td>100%</td>
<td>-</td>
<td>16</td>
<td>90.8±0.4</td>
</tr>
<tr>
<td>10%</td>
<td>90%</td>
<td>2.8</td>
<td>13.2</td>
<td>125.7±1.1</td>
</tr>
<tr>
<td>20%</td>
<td>80%</td>
<td>5.2</td>
<td>10.8</td>
<td>93.5±0.7</td>
</tr>
<tr>
<td>30%</td>
<td>70%</td>
<td>7.2</td>
<td>8.8</td>
<td>90.3±1.5</td>
</tr>
<tr>
<td>40%</td>
<td>60%</td>
<td>9</td>
<td>7</td>
<td>2199±83.5</td>
</tr>
<tr>
<td>50%</td>
<td>50%</td>
<td>10.5</td>
<td>5.5</td>
<td>1562±435.4</td>
</tr>
<tr>
<td>60%</td>
<td>40%</td>
<td>11.9</td>
<td>4.1</td>
<td>2026±674.2</td>
</tr>
<tr>
<td>70%</td>
<td>30%</td>
<td>13.1</td>
<td>2.9</td>
<td>1196±300.1</td>
</tr>
<tr>
<td>80%</td>
<td>20%</td>
<td>14.2</td>
<td>1.8</td>
<td>942±201.6</td>
</tr>
<tr>
<td>90%</td>
<td>10%</td>
<td>15.1</td>
<td>0.9</td>
<td>445±61.5</td>
</tr>
</tbody>
</table>

**Table 3.3.4.** Size and zeta potential of TLP3 at N/P 16 by DLS measurements.

<table>
<thead>
<tr>
<th>Targeted PEG Oligomer / Lipo-oligomer Molar Ratio</th>
<th>Individual N/P Ratios</th>
<th>Size (nm)</th>
<th>PdI</th>
<th>Zeta Potential (mV)</th>
</tr>
</thead>
<tbody>
<tr>
<td>-</td>
<td>100%</td>
<td>-</td>
<td>16</td>
<td>224±18.9</td>
</tr>
<tr>
<td>10%</td>
<td>90%</td>
<td>3.8</td>
<td>12.2</td>
<td>183±2.5</td>
</tr>
<tr>
<td>20%</td>
<td>80%</td>
<td>6.6</td>
<td>9.4</td>
<td>198±4</td>
</tr>
<tr>
<td>30%</td>
<td>70%</td>
<td>8.7</td>
<td>7.3</td>
<td>1046±427.2</td>
</tr>
<tr>
<td>40%</td>
<td>60%</td>
<td>10.4</td>
<td>5.6</td>
<td>2636±1153.2</td>
</tr>
<tr>
<td>50%</td>
<td>50%</td>
<td>11.8</td>
<td>4.2</td>
<td>1096±149.9</td>
</tr>
<tr>
<td>60%</td>
<td>40%</td>
<td>12.9</td>
<td>3.1</td>
<td>806±135.5</td>
</tr>
<tr>
<td>70%</td>
<td>30%</td>
<td>13.9</td>
<td>2.1</td>
<td>630±122</td>
</tr>
<tr>
<td>80%</td>
<td>20%</td>
<td>14.7</td>
<td>1.3</td>
<td>890±52.2</td>
</tr>
<tr>
<td>90%</td>
<td>10%</td>
<td>15.4</td>
<td>0.6</td>
<td>893±76.3</td>
</tr>
</tbody>
</table>
Figure 3.3.4. siRNA binding of TLP1 at N/P 16 determined by agarose gel shift assay. Folate-PEG24-K(Stp4-C)2 (356) as targeted PEG oligomer and C-Y3-Stp2-[(OleA)2-K]-K-Stp2-Y3-C (454) as lipo-oligomer were co-formulated according to different [targeted PEG oligomer / lipo-oligomer] molar ratios to form siRNA polyplexes. Free siRNA was used as control. Complete siRNA binding was marked in red rectangle.

Figure 3.3.5. siRNA binding of TLP2 at N/P 16 determined by agarose gel shift assay. Folate-PEG24-K(Stp4-C)2 (356) as targeted PEG oligomer and C-Stp2-[(OleA)2-K]-K-Stp2-C (49) as lipo-oligomer were co-formulated according to different [targeted PEG oligomer / lipo-oligomer] molar ratios to form siRNA polyplexes. Free siRNA was used as control. Complete siRNA binding was marked in red rectangle.

Figure 3.3.6. siRNA binding of TLP3 at N/P 16 determined by agarose gel shift assay. Folate-PEG24-K(Stp4-C)2 (356) as targeted PEG oligomer and (LinA)2-K-C-Stp3-C (229) as lipo-oligomer were co-formulated according to different [targeted PEG oligomer / lipo-oligomer] molar ratios to form siRNA polyplexes. Free siRNA was used as control. Complete siRNA binding was marked in red rectangle.
3.3.2 Receptor-mediated internalization and intracellular distribution of TLPs

To verify targeting capacity of the folate-linked TLPs, fluorescent Cy5-labeled siRNA was exploited to study the cellular internalization profile by flow cytometry, and FR-rich tumor cell lines as L1210, M109 and KB cells, and FR-deficient cell line as MCF-7 cells [67, 76, 78, 79] were subjected for the following experiments.

The cells were treated with TLPs at N/P 16 for 4 h at 37 °C, and then the uptake levels of TLPs were analyzed by flow cytometry (Figure 3.3.7A). All the TLP formulations exhibited strong cellular internalization in FR-rich cells. The uptake levels for the TLPs in L1210 cells were similar (91-93% positive cells), which were higher than the levels in M109 cells (76-81% positive cells). On the contrary, all the TLP formulations barely entered FR-deficient MCF-7 cells. For control studies, alanine-substituted oligomer \textit{188} and aforestated lipo-oligomers were co-formulated as non-targeted lipopolyplexes (NTLPs) (Table 3.3.5). In KB cells, the level of TLP1 (88% positive cells) was comparable as \textit{356} polyplexes (91% positive cells), while NTLP1 mediated insufficient cellular uptake. In short, these results gave evidence that TLPs were internalized in a FR-specific manner, and the folate conjugates were required for association with the target tumor cells.

The crucial question about the membrane association, translocation into cells and the following trafficking of TLPs remained obscure. A powerful tool to elucidate the internalization mechanism of TLPs is TEM [81], which has been employed to examine the cell entry processes and intracellular distribution of various macromolecules and particles [88, 89]. Nevertheless, among these, few studies have focused on the targeted delivery of siRNA [76, 90]. To locate the receptor in relation to the plasma membrane and cellular organelles, the primary antibodies against FR were visualized with Protein G-gold conjugate (6 nm in diameter). To map the siRNA molecules, biotinylated siRNA was labeled with neutravidin-gold conjugate (10 nm in diameter). These studies were performed during a research visit at Institute of Molecular and Cell Biology, University of Tartu.

<table>
<thead>
<tr>
<th>Table 3.3.5. TLP Formulations$^a$</th>
<th>Formulation</th>
<th>Targeted PEG Oligomer</th>
<th>Lipo-Oligomer</th>
</tr>
</thead>
<tbody>
<tr>
<td>NTLP1</td>
<td>A-PEG$<em>{24}$(K)(Stp$</em>{2}$-C)$_{2}$ (\textit{188})</td>
<td>C-Y$<em>{3}$-Stp$</em>{2}$-([\text{OleA}]<em>{2}-K)-Stp$</em>{2}$-Y$_{3}$-C (\textit{454})</td>
<td></td>
</tr>
<tr>
<td>NTLP2</td>
<td>C-\textit{356}-Stp$<em>{2}$-([\text{OleA}]</em>{2}-K)-Stp$_{2}$-C (\textit{49})</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NTLP3</td>
<td>(LinA)$<em>{2}$-K-C-Stp$</em>{2}$-C (\textit{229})</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

$^a$The sequence implies from C- terminal to N- terminal. C: cysteine; K: lysine; Y: tyrosine; PEG: polyethylene glycol; Stp: succinoyl-tetraethylene pentamine; OleA: oleic acid; LinA: linolic acid; K$^\alpha$ and K$^\epsilon$ refer to branchings by $\alpha$- and $\epsilon$-amino modification of lysines.
Figure 3.3.7. Folate receptor (FR)-mediated uptake and intracellular distribution of TLPs. (A) The cellular internalization capacity of TLPs was evaluated by comparing the uptake levels of siRNA polyplexes in FR-overexpressing L1210, M109 & KB vs. FR-deficient MCF-7 cells. siRNA polyplexes were prepared at N/P 16 with Cy5-labeled siRNA. The cells were incubated with siRNA polyplexes at 37 °C for 4 h before flow cytometric measurements. The amount of Cy5-positive cells was analyzed through excitation of the dye at 635 nm and detection of emission at 665/20 nm. (B-F) Immuno-TEM of FR-mediated endocytic pathway for TLP1 in FR-overexpressing KB cells. TLP1 was formed at N/P 16 with biotinylated-siRNA tagged with 10 nm neutravidin-gold particles. FR was visualized with anti-FR-α antibodies and Protein-G coupled to 6 nm gold particles (green arrowheads in the images or red dots in the scheme). The experiments were performed in collaboration with Dr. Kärt Padari (Institute of Molecular and Cell Biology, University of Tartu). (B) Association of siRNA polyplexes with the cell surface after incubation with siRNA polyplexes for 15 min. (C) The higher-magnification image of blue rectangle in (B) showed the association of siRNA polyplexes with FR. (D) The higher-magnification image of red rectangle in (B) showed membrane invagination. (E) The higher-magnification image of green rectangle in (D) indicated FR localizing in close proximity to siRNA polyplexes. (F) siRNA polyplexes localized inside the vesicular structure after 1 h.
Results

As demonstrated in Figure 3.3.7B, after incubating FR-positive KB cells with 10 nm gold label-containing TLP1 for 15 min, siRNA polyplexes were detected prominently as electron dense particles and associated quickly with the cell surface. In the higher-magnification image, siRNA polyplexes seemed to be in close contact with the FR (6 nm gold tags indicated by arrowheads in Figure 3.3.7C). Subsequently, the colocalization of siRNA polyplexes and the FR (indicated by red dots in the scheme of Figure 3.3.7D and arrowheads in the enlarged image as Figure 3.3.7E) induced morphological changes in the plasma membrane, leading to the formation of membrane invaginations. Later at 1 h, siRNA polyplexes shifted deeper into the cytoplasm, being finally fully engulfed by the cell into vesicles (Figure 3.3.7F), which resembled the structures of endolysosomal pathway. Besides, NTLP1 were very rarely detected at the cell surface, and this correlated well with the inefficient uptake level measured by flow cytometry in KB cells (Figure 3.3.7A).

Figure 3.3.8. Time-lapse confocal laser scanning microscopy (CLSM) for TLP1 transduction in KB cells. TLP1 was prepared at N/P 16 with AF 647-labeled siRNA (red). The nuclei (blue) were stained with Hoechst 33342. The yellow and gray rectangles were enlarged as (B) and (D), respectively. (A) Endosomes (green) were visualized with CellLight Late Endosomes-RFP. (B) Lysosomes (green) were marked with CellLight Lysosomes-GFP. The experiments were performed in collaboration with Dr. Xueying Liu (Innovation Center of NanoMedicine).

As a next step, the involvement of endo-/lysosomal compartments in the transport of TLPs was further differentiated upon a collaborative research visit at Innovation Center of NanoMedicine and University of Tokyo. To gain more detailed insights into the dynamics of TLPs, we formulated TLP1 with AF 647-labeled siRNA, labeled late endosomes with CellLight Late Endosomes-RFP, and lysosomes with CellLight Lysosomes-GFP, and performed time-lapse confocal laser scanning microscopy (CLSM) with cultured KB cells. Within 1 h (Figure 3.3.8A), AF 647-labeled siRNA (red) polyplexes were gradually associated with late endosomes (green), and the colocalization of siRNA and late endosomes was obvious after incubation for 1 and 3 h. As shown in the enlarged
image (Figure 3.3.8B), the overlap of two signals suggested that TLP1 was entrapped in late endosomes. Between 3 and 4 h, the association with late endosomes diminished; and expectedly, at the same time, the colocalization of siRNA polyplexes and lysosomes (green) became excessive (Figure 3.3.8C). As shown in Figure 3.3.8D, the majority of siRNA polyplexes were found to be inside lysosomes at 4 h.

Hence, these findings validated that TLPs were capable of efficient tumor cell-specific uptake, and a particular emphasis is placed on the intracellular distribution of TLPs during FR-mediated endocytosis. FR appeared to serve as a docking point for TLPs, and the binding of TLPs to receptors shortly induced internalization of siRNA polyplexes within 15 min. Afterwards, at 1–3 h, late endosomes most often governed the transduction of TLP1, and the vesicles trafficked through the endolysosomal pathway experiencing a gradual drop of pH, then siRNA polyplexes were finally targeted to lysosomes.
3.3.3 siRNA release and reporter gene silencing by TLPs

As most of TLPs retained their dense packing inside endolysosomal compartments after cellular uptake, it is crucial to understand whether the cargo can be released from the endosomal entrapments, reach to the cytoplasm and be available for RNAi machinery for mediating gene silencing. To shed further light on the siRNA release from TLPs by immuno-TEM, we incubated KB cells with TLP1 (N/P 16) for 4 h (Figure 3.3.9). Generally, these TLP1-containing vesicles were intact and surrounded by a continuous membrane. Occasionally, some of these vesicles had a discontinuous membrane, and the electron density of the vesicle content was undistinguishable from that of cytosol (Figure 3.3.9A). Moreover, single (Figure 3.3.9B) or a small cluster (Figure 3.3.9C) of gold particles were spread apparently free in cytosol, often in the close proximity of vesicles with discontinuous membrane. As a key role in the delivery of TLPs, internalized FR proteins (arrowheads in Figure 3.3.9B and D) were still associated with siRNA polyplexes.

![Figure 3.3.9](image-url)

*Figure 3.3.9. Morphological changes in TLP1-containing vesicles in FR-overexpressing KB cells at 4 h monitored by immuno-TEM. TLP1 was formed at N/P 16 with biotinylated-siRNA tagged with 10 nm neutravidin-gold particles. FR was visualized with anti-FR-α antibodies and Protein-G coupled to 6 nm gold particles (green arrowheads in the image). Discontinuous membrane of some endosomes resulted in endosomal escape of the siRNA molecules. (A) and (C) were accompanied by higher-magnification images, (B) and (D), respectively. The experiments were performed in collaboration with Dr. Kärt Padari (Institute of Molecular and Cell Biology, University of Tartu).*
Figure 3.3.10. Reconstructed KB cell showing the distribution of siRNA, late endosomes and lysosomes based on CLSM. KB cells were incubated with TLP1 (N/P 16) containing AF 647-labeled siRNA (red) for 4 h. Late endosomes (blue) were visualized with CellLight Late Endosomes-RFP, and lysosomes (green) were marked with CellLight Lysosomes-GFP. The experiments were performed in collaboration with Dr. Xueying Liu (Innovation Center of NanoMedicine).

Figure 3.3.11. The scheme interpreting the distribution of siRNA, late endosomes and lysosomes in reconstructed KB cell using CLSM.

In an attempt to confirm the dislocation of siRNA from endolysosomal compartments, the results obtained by TEM were complemented by analogous experiments with CLSM. TLP1 was complexed with AF 647-labeled siRNA at N/P 16, and KB cells were stained with CellLight Late Endosomes-RFP and CellLight Lysosomes-GFP. To avoid misleading interpretation based on spatial limitations, 3D reconstruction of serial images from single cell was utilized (Figure 3.3.10 and 3.3.11). As shown in Figure 3.3.10, lysosomes (green) were dominant, and late endosomes (blue) were scarcely distributed in the cell. Similarly, siRNA molecules (red) were largely overlapped with late endosomes (purple) or lysosomes (yellow). Notably, although at low frequency, escaping siRNA molecules were detectable (yellow arrowheads in Figure 3.3.10), suggesting TLP1 managed to deliver siRNA into cytosol.
We next planned to estimate the ability of TLP formulations to induce target gene silencing in the cancer cell culture models. For this, we formulated siRNA targeting eGFP (siGFP) or control siRNA (siCtrl) within the different TLP formulations and carried out the transfections in the KB/eGFPLuc cells, which are stably expressing eGFP-Luciferase (eGFPLuc) fusion protein, and evaluated target gene silencing via luciferase activity by luminometric analysis. As shown in Figure 3.3.12, all the TLP formulations containing siGFP at N/P 16 mediated significant gene silencing efficiency in KB/eGFPLuc cells, as 73-88% of luciferase activity was downregulated. This effect was superior to the parent polyplexes (55%). Among these TLP formulations, the most efficient gene silencing activity was achieved by TLP1 (88%). At the same time, polyplexes with siCtrl did not induce any unspecific gene silencing. Furthermore, non-targeted NTLPs formulations failed to reduce the reporter gene expression, highlighting that TLPs were taken up and able to invoke RNAi in the target cells by a specific manner. Very importantly, the parent oligomer had limited ability for endosomal escape, and for robust pharmacological activity, it required the presence of the endosomolytic Inf7 peptide modification on siRNA [33]. As indicated by the studies above, the novel formulation strategy enabled us to overcome this limitation and achieve very efficient gene knockdowns with simply regular siRNA (without the need for additional endosomolytic modification).

To conclude, TEM and CLSM demonstrated the intracellular mode of trafficking of the TLPs and their ability to release siRNA from endosomes to cytosol (i.e. the site-of-action of siRNA). Furthermore, the gene silencing assay confirmed that TLPs allowed the siRNA to be released from polyplexes after FR-mediated endocytosis, and showed remarkable target gene silencing effect.
3.3.4  Receptor-dependent antitumoral activity by EG5 gene silencing

As aforementioned, TLPs mediated impressive functional gene silencing in vitro, and hence we next sought to investigate, whether by siRNA against EG5 (siEG5) we could achieve cell-targeted cytotoxicity in FR-expressing tumor cells. We formulated TLPs with siEG5 and treated both FR-positive KB cells and FR-negative MCF-7 cells for 45 min.

Figure 3.3.13. Treatments of TLPs containing EG5-targeted siRNA (siEG5) or control siRNA (siCtrl) at N/P 16. (A) Metabolic activity of FR-positive KB and FR-negative MCF-7 cells at 48 h after treatment with TLPs. (B) KB cells treated with TLPs observed by DAPI staining under the fluorescent microscope. The mitotic blockade that was induced by EG5 knockdown caused "aster formation" of nuclear DNA (yellow arrows). The scale bars represent 10 μm. (C) mRNA level of EG5 gene measured by qRT-PCR at 48 h after transfection of TLPs in FR-positive KB and L1210 cells. GAPDH was used as housekeeping gene.
After incubation for 48 h, a metabolic activity assay was used for assigning cell viability upon the treatments with the formulations, which reflected that all the siEG5 TLP formulations initiated effective cell killing in KB cells (Figure 3.3.13A). Besides, siCtrl TLPs did not affect cell viability in KB cells, indicating EG5-mediated effect was specific. Also, experiments in FR-negative MCF-7 cells confirmed that EG5-containing TLP formulations did not have any cytotoxic effect on non-target cells, indicating that uptake and cytotoxicity of the formulation was driven by the folate-FR interaction (Figure 3.3.13A). Moreover, siEG5-mediated cytotoxicity by EG5 was also confirmed in another FR-overexpressing cell line M109 (Figure 3.3.14). Moreover, it has been demonstrated that EG5 protein downregulation by RNAi leads to a monopolar spindle formation and arrest of cells in prometaphase with a phenotype as aster formation of nuclear DNA [53, 91]. After incubation with siEG5 TLPs, Figure 3.3.13B illustrated such typical mitotic asters (indicated by yellow arrows) in KB cells by DAPI staining. As expected, no aster formation was observed in case of siCtrl TLPs treatments.

EG5-specific gene silencing at mRNA level was further examined by qRT-PCR in FR-expressing KB and L1210 cells. As seen in Figure 3.3.13C, treatments with all siEG5 TLPs triggered pronounced degradation of EG5 mRNA expression levels in both cell lines. Moreover, siCtrl treatment remained on bar with untreated group, indicating the specificity of the EG5 knockdown without off-target effect. It is of notice that TLP2 and TLP3 had very similar gene silencing activity by qRT-PCR, in line with the preceding silencing experiments in the eGFPLuc assay (Figure 3.3.12). Interestingly, in both silencing models, TLP1 was significantly more potent than the rest of formulations (92% in KB cells; 85% in L1210 cells).

These results provided clear evidence that folate-conjugated TLPs enabled efficient silencing of EG5 expression at mRNA level, followed by mitotic blockade and finally cell death, and these effects were mediated by the presence of the FR on the cancer cells. Whereas, further studies were required to discern the potential factors for the different gene silencing potencies of different TLPs.
3.3.5  siRNA release kinetics and stability in cells

Although all the TLPs induced comparably efficient cellular uptake in FR-expressing cells (Figure 3.3.7A), gene silencing ability for different TLPs varied for some reason (Figure 3.3.12 and 3.3.13C). To explore the underlying mechanisms, with a focus on molecular pharmacokinetics, we examined the translocation of siRNA from endosomes to cytosol after transfection to estimate endosomal escaping capability profile of each formulation. The intracellular distribution of AF 647-labeled siRNA polyplexes was analyzed by co-staining of late endosomes and lysosomes using LysoTracker Green in KB cells with CLSM. As presented in Figure 3.3.15A, colocalization (yellow) of AF 647-labeled siRNA (red) with late endosomes and lysosomes (green) was monitored at 2 and 4 h. As previously shown in Figure 3.3.8, the TLP-containing vesicles were actively shifted from late endosomes to lysosomes between 3 h and 4 h after transfection, where TLPs experienced gradual acidification.

![Figure 3.3.15. Colocalization of siRNA polyplexes with late endosomes and lysosomes was presented by CLSM. (A) Intracellular distribution of AF 647-labeled siRNA (red) polyplexes in KB cells at 2 and 4 h after transfection for 45 min. Late endosomes and lysosomes were stained with LysoTracker Green (green). Nuclei were stained with DAPI (blue). (B) After tranfection for 45 min, colocalization ratios of AF 647-labeled siRNA with late endosomes and lysosomes were calculated using ZEN 2.1 software at 2 and 4 h. The experiments were performed in collaboration with Dr. Xueying Liu (Innovation Center of NanoMedicine).](image-url)
Furthermore, we observed a significant decrease in the colocalization ratios of all the TLPs in late endosomes and lysosomes (green) at 4 h after transfection (Figure 3.3.15B), indicating the onset of siRNA release from endosomes began during acidification of endolysosomal structures. Colocalization ratios of TLP1 were significantly higher than those of TLP2 and TLP3 at both 2 h and 4 h. This suggested that TLP2 and TLP3 had earlier endosomal escape capacity than TLP1. On the other hand, it seemed that sustained release of siRNA from endosomes to cytosol caused the enhanced gene silencing effect of TLP1, which corresponded with the results measured 48 h after transfection of TLPs (Figure 3.3.12 and 3.3.13C). As mentioned in literature, the decrease in intravesicular pH takes time along the endolysosomal pathway from pH 6.0–6.5 in early endosomes to pH 4.5–5.5 in late endosomes and lysosomes [92, 93], escaping of siRNA from vesicular compartments in response to dropping intravesicular pH for different TLP formulations may occur in different time courses.

In light of effective gene silencing effect, intracellular siRNA stability must also be taken into consideration. Through fluorescence resonance energy transfer (FRET) analysis, we aimed to track the stability and degradation of siRNA delivered by different TLP formulations in FR-expressing KB and L1210 cells. For this purpose, Cy5/TAMRA double-labeled siRNA was utilized: on the sense strand of siRNA, Cy5 was conjugated at the 5’ end, and TAMRA was at 3’ end. After Cy5/TAMRA double-labeled siRNA transfection for 1, 4, and 48 h, FRET intensity of cells was analyzed with flow cytometry by exciting the cells with a 488 nm laser and monitoring the fluorescence emission through a 660/20 nm filter. The mean FRET intensity of each TLP formulation was calculated by using FACSDiva software (Figure 3.3.16).

**Figure 3.3.16.** Intracellular fluorescence resonance energy transfer (FRET) signals were analyzed by flow cytometry at 1, 4 and 24 h after Cy5/TAMRA double-labeled siRNA transfection for 45 min in KB and L1210 cells. The samples were excited with a 488 nm laser, and their emission was monitored by using a 660/20 nm filter. The experiments were in collaboration with Naoto Yoshinaga (Department of Bioengineering, University of Tokyo).
Because FRET efficiency falls off as $1/R^6$, observation of FRET is typically limited to donor/acceptor distances of about 10 nm [94], and, therefore, FRET is only measurable when siRNA duplexes remain intact inside cells, otherwise the degradation of siRNA results in the loss of FRET. In KB cells, all the TLPs maintained high FRET intensity at 1 h. At 4 h, FRET intensity of TLP1 dropped only slightly by 7%, in contrast to TLP2 (loss by 39%) and TLP3 (loss by 24%), showing that siRNA remained intact in case of TLP1 formulation. Although FRET intensity of TLPs decreased up to 90-95% within 24 h, notably, FRET intensity of TLP1 remained 2-fold higher compared to TLP2 and TLP3. Similarly, in L1210 cells, FRET intensity of TLP1 was higher than those of TLP2 and TLP3 after incubation for 1 h, and similar trend was found at 24 h.

Additional proof of siRNA stability was obtained by CLSM in cultured KB cells transfected with Cy5 (red) and TAMRA (green) double-labeled siRNA. Lysosomes were labeled with CellLight Lysosomes-GFP (blue). As demonstrated by the representative examples in Figure 3.3.17, TLP1 showed extensive colocalization of the two fluorophores (yellow), i.e. intact siRNA, after incubating the cells for 1 h. Red or green pixels indicating the degraded siRNA molecules were also observed. Impressively, after 24 h, despite most of siRNA sequences were degraded by lysosomes, intact siRNA was still detectable. On the contrary, without 454, 356 protected only few intact siRNA molecules at 1 h, and none at 24 h.

![Figure 3.3.17](#) FRET imaging of Cy5 (red)/TAMRA (green) double-labeled siRNA at 1 and 24 h after transfection for 45 min in KB cells by CLSM. Colocalization of the two fluorophores (yellow) indicated intact siRNA. Lysosomes were labeled with CellLight Lysosome-GFP (blue). The scale bars represent 10 μm. The experiments were in collaboration with Dr. Xueying Liu (Innovation Center of NanoMedicine).
To conclude, on the condition that there was no significant difference for cellular internalization levels for TLPs, TLP1 is hypothesized to unload siRNA in a rather sustained manner based on the delayed shift in colocalization with late endosomes/lysosomes. Furthermore, TLP1 exhibited superior ability to confer the protection and stability of siRNA compared to the other formulation, as measured by a distance-dependent FRET-based approach. Since TLP2 and TLP3 did not show significant difference regarding endosomal escaping capability, siRNA stability and biological activity, it appeared that the modification of tyrosines to the fatty acid-based TLP1, which provides further stability to the polyplex, was essential for the increased activity of the formulations.

3.3.6 Tumoral delivery and gene silencing upon systemic administration

From the drug delivery standpoint, systemic delivery of siRNA poses a great challenge, since siRNA is readily degraded by serum endonucleases and is easily eliminated by glomerular filtration with a short plasma half-life of <10 min [95]. In order to understand whether TLPs could improve the distribution profile of siRNA, folate-conjugated TLP1, the most potent formulation in vitro with favorable size and surface charge, was selected for the further in vivo studies. The two single oligomer components of TLP1, i.e. PEGylated folate-equipped oligomer (356) and tyrosine-based oleic acid oligomer (454), were used for comparison. Non-targeted analogue NTLP1 and naked siRNA were also exploited as controls. FR-expressing L1210 tumor cells were implanted subcutaneously in nude mice. We formulated different Cy7-labeled siRNA (at the dose of 50 µg of siRNA) polyplexes at N/P 16, and administered these siRNA polyplexes intravenously (i.v.). The biodistribution of Cy7-labeled siRNA measured by near infrared (NIR) fluorescence imaging was demonstrated in Figure 3.3.18A. As Cy7-labeled siRNA spread throughout the whole body along with the blood circulation immediately after injection, Cy7 signal of naked siRNA lasted for merely 30 min. PEGylated folate-equipped oligomer 356 formed nanoparticles with a diameter of ~6 nm, approached the tumor site with small fraction of Cy7 signal at 15 min, and transiently disappeared after 30 min. Meanwhile, tyrosine-based 454 (100-130 nm in diameter) significantly improved the systemic retention of siRNA >4-fold over naked siRNA and 356. For that the volume of blood circulates through the tumor is usually far less than that of the arteries, only the nanoparticles that are not rapidly cleared from the circulation will have a chance to encounter the leaky tumor vasculature for targeting [96]. Accordingly, TLP1, as an optimized co-formulation of 356 and 454, has not only mediated comparably prolonged systemic retention as 454, more advantageously, but also enhanced tumoral siRNA delivery within 2 h. Notably, Cy7 signal was detectable in harvested tumors only from TLP1-treated animals at 2 h, while there was no Cy7 signal in the rest of groups including folate-linked 356 (Figure 3.3.18B). As non-targeted
control, NTLP1 resulted in similar circulation profile as TLP1 but siRNA barely reached the tumor site, thus it revealed an explicit difference for the functionality of folate ligands.

**Figure 3.3.18.** Biodistribution of TLP1 at N/P 16 in NMRI-nude mice bearing L1210 tumors via i.v. administration determined by NIR fluorescence bioimaging. 50 μg of Cy7-labeled siRNA was formulated with TLP1, NTLP1, PEGylated folate-conjugated oligomer 356, or tyrosine-conjugated oleic acid oligomer 454 as carrier. Experiments were performed with 3-4 animals per group; a representative animal of each group is shown. (A) Time-dependent tumoral retention of siRNA polyplexes over 24 h. Lateral views of animals were shown to present the tumor sites (dotted circles). (B) Tumors harvested 30 min and 2 h after injection of siRNA polyplexes. The experiments were performed in collaboration with Eva Kessel (Dr. med. vet. study, Department of Pharmacy, Ludwig-Maximilians-Universität München).
Upon systemic administration of siRNA polyplexes, the elimination profiles were presented in Figure 3.3.19. It is known that despite the formulation can be modified to prolong blood circulation, but non-specific distribution in the highly perfused organs including liver, kidneys and lung has thus far been inevitable [86]. In addition, several in vivo studies have reported that kidneys are prevailing in siRNA elimination [95], and the pore size of the glomerular filtration barrier is roughly 8 nm [97]. Not surprisingly, due to small particle size of 356 (6 nm in diameter), Cy7-siRNA immediately passed through glomeruli and was excreted into the urinary bladder within 1 h. For the purpose of circumventing rapid renal clearance, siRNA polyplexes should have a particle size of about 50-300 nm [98]. Interestingly, TLP1, with a diameter of 127 nm, seemed to take advantage of its component 454 to greatly reduce kidney uptake and increase systemic retention of siRNA for 4 h. Identical impact of 454 on the distribution profile can be also found in case of NTLP1.

**Figure 3.3.19.** Biodistribution of TLP1 at N/P 16 in NMRI-nude mice bearing L1210 tumors via i.v. administration determined by NIR fluorescence bioimaging. 50 μg of Cy7-labeled siRNA was formulated with TLP1, NTLP1, PEGylated folate-conjugated oligomer 356, or tyrosine-conjugated oleic acid oligomer 454 as carrier. Experiments were performed with 3-4 animals per group; a representative animal of each group is shown. (A) Distribution and elimination of siRNA polyplexes over 24 h. Animals were presented in the ventral view. (B) Tumors and organs harvested 1 h and 24 h after injection of siRNA polyplexes. The experiments were in collaboration with Eva Kessel (Dr. med. vet. study, Department of Pharmacy, Ludwig-Maximilians-Universität München).
After clarifying that FR-specific TLP1 successfully delivered siRNA to the tumor via i.v. injection, we sought to validate the functional gene silencing of TLP1 *in vivo*. For this aim, we formulated TLP1 with siEG5 or siCtrl (50 µg of siRNA), and administered these siRNA polyplexes i.v. in the L1210 tumor-bearing mice twice. 24 h after the last treatment, we harvested the tumor, extracted RNA and measured the EG5 mRNA levels by qRT-PCR (Figure 3.3.20A). Compared to untreated controls, the siEG5 TLP1 induced significant downregulation of EG5 expression by 65%. Importantly, siCtrl TLP1 showed negligible effects on mRNA level of EG5 as compared with untreated tumors.

Systemic circulation of siRNA polyplexes might also lead to exposure to non-target tissues which might cause potential side effects; we therefore monitored the body weights and carried out blood biochemistry examinations to help us realize the biocompatibility of TLP1. As shown in Figure 3.3.20B, the body weight curves indicated that the treatments were well-tolerated compared to untreated controls. The blood samples were collected 24 h after the treatments to determine four relevant clinical biochemistry parameters (ALT, AST, BUN and creatinine). Increased liver enzymes (ALT and AST) would indicate formulation-associated liver damage or acute hepatitis, while elevated BUN or creatinine would be related to renal malfunctions. As presented in Table 3.3.6, in the treatment groups, the levels of ALT and AST were in a range equivalent to the untreated control group. In context of creatinine and BUN, there was no significant difference, either.
Table 3.3.6. Clinical biochemistry parameters (ALT, AST, BUN and creatinine). Plasma was obtained from the treated animals 24 h after the second injection (n = 5) compared to untreated tumor-bearing mice (n = 3) that were euthanized on the same day.

<table>
<thead>
<tr>
<th></th>
<th>ALT (U/L)</th>
<th>AST (U/L)</th>
<th>Creatinine (mg/dL)</th>
<th>BUN (mg/dL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>TLP1 + siEG5</td>
<td>39 ± 2</td>
<td>120 ± 31</td>
<td>0.09 ± 0.01</td>
<td>40 ± 8</td>
</tr>
<tr>
<td>TLP1 + siCtrl</td>
<td>57.4 ± 25</td>
<td>130 ± 46</td>
<td>0.09 ± 0.01</td>
<td>39 ± 7</td>
</tr>
<tr>
<td>Untreated</td>
<td>46 ± 15</td>
<td>113 ± 23</td>
<td>0.07 ± 0.01</td>
<td>38 ± 7</td>
</tr>
</tbody>
</table>

To draw a conclusion, these encouraging results suggested that TLP1 delivered siRNA to the tumor within 2 h via i.v. injection, inducing specific RNAi-mediated degradation of EG5 mRNA in the tumor tissue. Moreover, no indication for potential side effects was given based on the body weight analysis and in clinical chemistry measurements from the blood.
4 Discussion

4.1 Oligoglutamyl-MTX-conjugated nanoplexes

One effective approach in cancer therapy is the use of a combination therapy with different therapeutic agents, allowing to tackle the disease from different angles. While such approaches with standard chemotherapeutic drugs are effectual and usually decrease the likelihood for chemoresistance, they still lack specificity and are associated with considerable toxicity. Novel gene therapeutic tools, such as RNAi, offer very interesting alternatives for modulating such therapy as they process sequence-specific gene silencing implicated in cell division, and importantly, may be used in combination with classical chemotherapeutic drugs. Another crucial aspect in cancer therapy is to be able to overcome or significantly decrease the side effects and associated toxicities of the therapeutics. The aim in this work was to combine two different antitumoral agents (the chemical DHFR inhibitor MTX and the mitosis-inhibiting EG5 siRNA) into one nanoparticle drug. Therein we took advantage of the bifunctional MTX which has been recently shown to possess potential as both cytotoxic drug and targeting ligand in a cancer combination therapy approach for the co-delivery of cytotoxic poly(I:C) [50]. As part of a multifunctional nanoplex, MTX was also supposed to facilitate targeted delivery of antitumoral EG5 siRNA to the tumor cells.

The structure of the used oligoaminoamides is based on analogous folate-containing two-arm branched oligomers with receptor-targeted gene silencing capacity in vitro and in vivo [33]. The artificial oligoamino acid succinoyl tetraethylene pentamine (Stp) together with natural amino acids (lysine, cysteine) serve as siRNA binding carriers, a PEG chain provides nanoplex shielding. In the current work, MTX derivatives acted as targeting ligand. As measured by FCS (Table 3.1.2), AFM (Figure 3.1.4) and TEM (Figure 3.1.5), these MTX conjugates electrostatically complexed siRNA and formed compact homogeneous spherical nanoparticles with hydrodynamic diameter of ~6 nm. The branched two-arm structure containing several Stp units provided the positive charge for siRNA binding, and two cysteines further stabilized the polyplex via disulfide crosslinking. As a result of the PEGylation, the surface charges of polyplexes were almost neutralized, which not only prevented aggregation, but also shielded the particles from unspecific cationic association and allowed for specifically presenting the targeting ligand to the cells. Considering that these polyplexes were only ~1.3 fold larger than free siRNA, it indicated that these PEGylated glutamyl-MTX conjugates were associated with single siRNA in a
monomolecular fashion, in line with the previous results with the PEGylated folate-conjugated oligomer [33].

The cellular uptake studies demonstrated that the MTX oligomer conjugates were taken up into cells in a FR-specific fashion, as the polyplexes were avidly binding to FR-expressing KB cells while only negligible staining was seen in FR-negative A549 cells. Furthermore, in the competition assay, binding of polyplexes was blocked by preincubation with excess free folate or MTX. We also verified FR-specific targeting effect of MTX conjugates by a series of functional siRNA-mediated gene silencing assays in comparison between KB and FR-deficient MCF-7 cell lines. In the literature, the relationship between tumor response to MTX and FR expression has been extensively investigated. First, KB cell sublines with below-wildtype FR expression show resistance for MTX [99], while the cell lines lacking functional RFC are also commonly resistant to MTX [100]. Second, the IC50 of MTX for the cells co-expressing RFC after transfection with FR-α is the same as for the wild type [101], whereas MTX is active in cell lines that are RFC-deficient but overexpress FR-α [102, 103]. In addition, it has been reported that transfection of MCF-7 cells which do not express FR with FR cDNA increases MTX uptake and cytotoxicity [78]. It has been also shown that FR-mediated transport of MTX is highly energy-requiring and ceases rapidly when energy metabolism is blocked [104]. Moreover, MTX has been coupled to many natural and synthetic carriers, resulting in either amide or ester bond formation. The use of either conjugation or encapsulation approaches could change the cellular transport characteristics, pharmacokinetics and pharmacodynamics of the parent drug, resulting in increased or decreased cytotoxicity, along with altered in vivo distribution [105, 106]. For example, the uptake of a PAMAM dendrimers covalently conjugated with MTX is taking place in a FR-dependent manner in KB cells [71], and a polyvalent dendrimer-MTX conjugate is not toxic to FR-negative cells [107]. More importantly, polyglutamylation of the MTX at its γ-carboxylic acid is known to prevent transport of MTX across the membrane by RFC [108], and the oxidized pteridine ring as well as a glutamate tail are required for the greatest FR-α affinity [109]. In contrast to free MTX which could also enter the cell through the RFC, our findings confirmed a FR-specific uptake of MTX conjugated siRNA polyplexes.

Following FR-mediated internalization, the siRNA-linked endosomolytic Inf7 peptide is supposed to enhance endosomal escape into the cytosol, where the crosslinking disulfide bridges of the oligomer coat are thought to be cleaved within the reductive intracellular environment in order to release the siRNA and glutamylated MTX conjugates. In KB/eGFPLuc cells, all of these
polyplexes (638-642) mediated successful gene silencing potency with Inf7-modified siGFP (Figure 3.1.9). Among the MTX conjugates, 640 exhibited the best performance, and higher N/P ratios further enhanced the transfection efficiency. Lack of Inf7 peptide in the siRNA construct reduced the gene silencing potency (Figure 3.1.10). Consistent with prior work with free oligomer conjugates and poly(I:C) complexes [50], oligo-glutamyl MTX conjugates (639, 640 and 641) were found to be more cytotoxic than free MTX (Figure 3.1.12). One explanation is that conjugated MTX could be internalized in higher quantities than free MTX in this model. Moreover, the glutamylation degree of MTX conjugates correlates to DHFR inhibition potency [50], which results in suppression of downstream effects on thymidylate and purine synthesis, and might be responsible for enhanced potency. In the experiments directly comparing the EG5 siRNA-mediated cytotoxicity in KB cells, it showed that in general MTX conjugates elicited considerably higher cytotoxicity levels compared to the folate analogue 356. Also, the inhibitory efficacy of the conjugates seemed to be related to the increasing degree of polyglutamylation from 638 (MTX-Stp) to 641 (6E-MTX-Stp). The tetraglutamylated 640 and hexaglutamylated 641 siRNA polypeplexes induced the most significant cytotoxicity, therefore this might indicate that the degree of polyglutamylation not only increased the MTX cytotoxicity but also potentiated the siEG5-dependent cytotoxicity in KB cells (Figure 3.1.12).

In the present study, upon i.t. administration of MTX-based 640 polypeplexes showed significantly increased intratumoral retention time and achieved levels comparable or even exceeding the folate-based 356 polypeplexes, and the remaining Cy7 signal in the 640-treated tumor was higher than 356-treated tumor after 168 h (Figure 3.1.15). In vivo distribution of siRNA polypeplexes is dependent on (1) the physicochemical properties of the carrier, (2) the nature of the siRNA, and (3) the anatomy and physiology of the drug distribution site. Once the siRNA polypeplexes have been injected into the interstitial space in the tumor, they have to avoid interactions with the extracellular matrix (including collagens, proteoglycans, hyaluronic acid, fibronectin, and other glycoproteins) such as binding, dissociation, or aggregation. MTX-conjugated 640, folate-conjugated 356 and alanine-substituted 188 polypeplexes were all PEGylated, which decreased the surface charge close to neutrality, and consequently avoided associating with these components. PEG molecules as hydrophilic domains were also vital for particle stabilization to prevent aggregation of polypeplexes. Moreover, the particle size is known to be intrinsically related to the rate of clearance from the blood circulation. Nanosized 356 or 640 polypeplexes are as small as abundant pores present in normal tissue endothelium [110], allowing good tissue penetration and slower removal from the circulation compared to free siRNA. Furthermore, considering that
the interstitial or extracellular pH in solid tumors is generally acidic, and the FR-α transport route has an affinity for folate that is comparable to that of MTX at low pH [111], such environment is beneficial for MTX conjugate 640 to compete with endogenous folate (N-5-methyltetrahydrofolate) for receptor binding and the following cellular internalization in KB xenograft tumors.

This study developed a molecule-defined nanoplex with bifunctional MTX ligand for effective intratumoral delivery of siRNA, which represents a challenging hurdle for the widespread application of RNAi in cancer research and therapy. First, the tetraglutamylated MTX of 640 showed greater in vivo KB tumor inhibition compared to equivalent free MTX (Figure 3.1.20A), validating the potentiated efficacy resulting from the degree of polyglutamylation. Second, 640 siRNA polyplexes (with siEG5-Inf7 or siCtrl-Inf7) led to significantly improved tumor suppression over free 640 (Figure 3.1.17A), which was expected to diffuse quickly after the administration because free 640 in the absence of siRNA failed to form nanoparticles. In addition, the endosomolytic Inf7 peptide contained within the siRNA polyplexes may facilitate the cytosolic delivery of polyplex-linked MTX molecules, enhancing their toxicity. In this respect, the co-delivery of siRNA/drug combinations by chemical or physical linkage into the same nanoparticle may present a therapeutic advantage in cancer treatment [112]. Encouragingly, the dual antitumoral mechanisms consisting of MTX-conjugated 640 and EG5 siRNA have shown enhanced antitumoral potency with 50% of recurrence-free survival (Figure 3.1.17C).
4.2 Targeted combinatorial polyplexes (TCPs)

By co-formulation strategy, TCP formulations presented different particle sizes and reduced surface charges as measured by DLS. These siRNA polyplexes were uniform compact nanoparticles without aggregates observed by TEM (Figure 3.2.3A), and siRNA complexation was verified by agarose gel shift assay (Figure 3.2.3B).

Measured by flow cytometry, the folate-based TCPs bound to FR-expressing L1210 and M109 cells in a receptor-specific pattern (Figure 3.2.4A). Characterization of the cellular uptake of TCPs in FR-positive KB cells by immuno-TEM further revealed the interaction of the siRNA polyplexes with FR at the plasma membrane and induction of their internalization via FR-mediated endocytosis. After internalization, the siRNA polyplexes mainly distributed in endocytic vesicles, where the FR remained in contact with TCPs and retained the colocalization. Upon longer incubation time, the membrane of TCP-containing vesicles became unstable and discontinuous, the tight clusters of siRNA polyplexes started to dissociate. Consequently, the occasional escape from endosomes and single TCP distribution to the cytosol was noted (Figure 3.2.4).

Endosomal entrapment is widely recognized as the main obstacle that limits the application of therapeutic nanocomplexes, whose target is in the cytoplasm or in the nucleus. It is of notice that oligoaminoamides were designed to act as PEI-like proton sponge motifs; by becoming increasingly protonated during acidification of endolysosomal structures, and to cause osmotic swelling of endosomes and release of the siRNA molecules upon vesicle rupture [42, 113, 114]. Published studies in the field of FR-targeted therapeutics have mainly focused on their role in bioactivity, but exact cellular trafficking has not been well studied so far. To our knowledge, this is the first time when immuno-TEM was applied to clarify the interactions of siRNA polyplexes and FR.

As shown in Figure 3.2.5, Inf7 peptide is necessary for efficient transfection of siRNA for TCPs and 356. Besides, recently we verified that the uptake of 100-200 nm FR-targeted polyplexes could be blocked completely by excess free folate, while the agglomerated large particles (>200 nm) might partially undergo receptor-independent uptake and gene silencing [115]. The luciferase activity in KB/eGFPLuc cells treated with controls, including siCtrl polyplexes and siCtrl-Inf7 polyplexes were similar to untreated cells, suggesting that there’s no intrinsic cytotoxicity of TCPs. Taken together, the gene silencing assay further showed that folate-containing TCPs allowed the Inf7-modifed siRNA polyplexes to access the cytosol, and showed not only gene-specific
silencing ability but also lack of cytotoxicity mediated by TCPs in KB/eGFPLuc cells.

After systemic administration, there are many ways by which siRNA carriers leave the bloodstream, including redistribution into the liver, spleen, kidneys and lung, nonspecific distribution has thus far been unavoidable; however, entering kidneys is the most common pathway [86]. The glomeruli in kidneys work as a filtration barrier that removes water and small molecules as urine while larger molecules are retained in the blood stream [116]. For mice, the excretion through kidneys typically occurs for molecules less than 30 kDa in size [117]; the molecular weight of naked siRNA is about 13 kDa [6], which readily passes glomerular fenestration and accumulates in urine. Aimed to avoid immediate glomerular filtration, we increased the particle size by introducing 3-arm Stp oligomers with larger size, and showed preliminary improvement on circulation time and therefore increased chance for TCPs to extravagate into the FR-expressing tumor.

In addition, to overcome steric hindrance surrounding the FR on the cell surface [118], a PEG linker was utilized to conjugate the oligomer to folate. PEGylation can minimize the protein binding and possibly attributes to the low clearance by the reticuloendothelial system or accumulation in related organs especially the liver [119], as extremely low Cy7 signal in liver and spleen was detected (Figure 3.2.7D). On the other hand, the hydrophilic nature of PEG might facilitate the renal excretion of TCPs [120].

Therefore, encouragingly, these results suggested that siEG5-Inf7 TCP1 successfully reached the target tissue via i.v. injection, rendering gene silencing in the tumor. It is considered that low toxicity is as important as functional activity; if siRNA delivery provoked unacceptable toxicity on either a cellular or systemic level, even the most effective siRNA delivery system would be vainness [121]. Thus it is important that the blood analysis gave no indication for toxicity affecting vital organs like liver or kidneys regarding TCPs.
4.3 Targeted lipopolyplexes (TLPs)

By co-formulation strategy, TCP formulations presented different particle sizes and reduced surface charges as measured by DLS. These siRNA polyplexes were uniform compact nanoparticles without aggregates observed by TEM (Figure 3.2.3A), and siRNA complexation was verified by agarose gel shift assay (Figure 3.2.3B).

In addition, the size of the administered siRNA polyplexes is one of the most important characteristics because it might affect uptake efficacy, kinetics, and internalization mechanisms [122]. The size limit for nanoparticles to undergo receptor-mediated endocytosis is about 100–200 nm [123, 124]. Shape can also affect the cellular uptake of nanoparticles, for example, spherical particles are taken up by cells more efficiently compared with the rod-shaped particles [122].

Notably, escaping siRNA molecules from endosomes were detected by TEM and CLSM (Figure 3.3.8), suggesting TLP1 managed to deliver siRNA into cytosol. One reasonable assumption is that the oligoaminoamides may act as proton sponge motifs to become increasingly cationized during endolysosomal acidification and, supported by the attached fatty acid domains, destabilize the lipid membrane [42, 125].

Most transfection reagents, e.g. RNAiMAX, Ribojuice, and Hiperfect, have a disassembly half-life of siRNA that falls in the range of 30 min to 2 h in HeLa cells [126], suggesting the intracellular milieu is challenging to siRNA integrity. It has been revealed that reactive oxygen species (ROS) and reactive nitrogen species (RNS) serve as messengers in cell signaling but also pose a potential oxidative damage to macromolecules, including nucleic acids [127]. And different FRET intensity profiles for certain TLP formulation in KB and L1210 cells may result from different reducing environments in different cell lines [128-130]. For that the rapid decrease of FRET intensity may relate to rapid degradation of siRNA delivered by TLP2 and TLP3, this effect was possibly attributed to the less potent gene knockdown. In contrast, TLP1 as the only formulation with containing stabilizing tyrosine trimers [36, 37] improved the siRNA stability and thus might foster the access to the RNAi machinery.

PEG as the shielding agent has been proven to be valuable in preventing non-specific interactions and avoiding immune recognition in the circulation [131]; however, another major barrier, liver, still accumulates the most of PEGylated nanoparticles [98]. In the liver, Kupffer cells recognize the opsonized nanoparticles via the scavenger receptor [119]. In accordance with the literature,
abundant Cy7-siRNA of TLP1 ended up in the liver (Figure 3.3.19); besides, it is also possible that these fatty acid-containing siRNA polyplexes with larger size (454, TLP1 and NTLP1) were prone to be further metabolized by liver. In the end, recent efforts have focused on the impact of particle stability on the pharmacokinetic profile and gene silencing efficiency *in vivo* [132]. It is believed that the biodistribution of siRNA polyplexes is the deciding factor for better efficacy, thus there is an ongoing need to improve the formulation stability and following circulation time in the future.
5 Summary

It is now widely recognized that efficient intracellular siRNA delivery to target sites in the body is the most important hurdle for clinical applications of RNAi [31]. Hence, to formulate siRNA molecules with an appropriate biocompatible delivery system is necessary for improving biological stability, targeted cellular uptake, and the pharmacokinetics of siRNA [133]. Herein different siRNA formulations were developed to target folate receptor (FR)-overexpressing tumors.

In the first part, the antifolate drug methotrexate (MTX), a well-established chemotherapeutic agent, serves as both targeting ligand and anticancer agent, was conjugated with glutamyl units to the PEGylated Stp backbone. The oligomers formed uniform spherical siRNA polyplexes with a hydrodynamic diameter of approximately 6.5 nm. These polyplexes accessed KB cells by binding to the folate receptor in a MTX-dependent manner and induced efficient gene silencing activity in vitro. Impressively, by i.t. administration, MTX-conjugated polyplexes significantly increased the intratumoral retention (168 h) of the siRNA, as compared to alanine-substituted non-targeted control polyplexes (48 h). The combination of MTX-conjugated polyplexes and EG5 siRNA provided enhanced antitumoral potency with 50% of recurrence-free survival of KB tumor-bearing mice.

In the next part, we sought to improve the pharmacokinetic profile of siRNA polyplexes. To achieve this, we optimized the physicochemical properties of polyplexes by combinatorial optimization of PEGylated folate-conjugated oligomer (for FR targeting and shielding of surface charges) and 3-arm oligomer (for size modification and particle stability). For uni-directional fast coupling between the two groups of oligomers, we activated the cysteine thiol groups of one of the oligomers with 5,5’-dithio-bis(2-nitrobenzoic acid) to achieve a fast chemical linkage through disulfide formation with the free thiol groups of the other oligomer. These targeted combinatorial polyplexes (TCPs) were homogeneous spherical particles with favorable size and surface charge, which showed strong siRNA binding activity. TCPs were internalized into cells by FR-mediated endocytosis, triggered significant eGFP-luciferase marker gene silencing, and transfection with antitumoral EG5 siRNA suppressed cell proliferation in FR-expressing tumor cells. Moreover, the most promising formulation TCP1 after i.v. administration in L1210 tumor-bearing mice exhibited siRNA delivery into the tumor, resulting in 46% EG5 gene silencing at mRNA level without noticeable side effects.
Furthermore, by co-formulation of a targeted PEGylated oligomer and a lipo-oligomer, folate-equipped targeted lipopolyplexes (TLPs) for targeted siRNA delivery were generated. TLPs formed spherical homogenous particles with neutralized surface charge in complex with siRNA. After active tumor-specific uptake via FR-mediated endocytosis, TLPs effectively unpacked siRNA between 2 and 4 h in response to dropping intravesicular pH, and mediated significant gene silencing efficiency in the target cells, as 73-88% of luciferase activity was suppressed. TLPs loaded with siEG5 further triggered profound EG5 gene suppression, leading to mitotic arrest and following strong cytotoxicity in FR-expressing tumor cells. In these formulations, tyrosine-modified TLP1 with a diameter of 127 nm, has been proven to enable the best intracellular stabilization and sustained release of siRNA, thus inducing the superior gene silencing efficiency. By i.v. administration in L1210 tumor-bearing mice, TLP1 demonstrated tumoral retention of siRNA within 2 h and achieved EG5 gene silencing by 65% without noteworthy side effects.

Taken together, these siRNA formulations were generated based on precise chemistry, displayed excellent ability for tumor-targeted delivery and gene silencing upon in vivo application, and could be expected to facilitate the future translation of RNAi-based nanomedicine for cancer treatment.
Abbreviations

AGO        Argonaute
AF         Alexa Fluor
AFM        atomic force microscopy
ALT        alanine aminotransferase
AST        aspartate aminotransferase
BUN        blood urea nitrogen
CLSM       confocal laser scanning microscopy
DAPI       4',6-diamidino-2-phenylindole
DBU        1,8-diazabicyclo[5.4.0]undec-7-ene
Dh         hydrodynamic diameter
DPEA       N,N-diisopropylethylamine
DLS        dynamic light scattering
DMEM       Dulbecco’s modified Eagle’s medium
DMSO       dimethylsulfoxide
DODT       3,6-dioxa-1,8-octanedithiol
DOPC       1,2-dioleoyl-sn-glycero-3-phosphocholine
DHFR       dihydrofolate reductase
DMF        dimethylformamide
DTNB       5,5-dithio-bis(2-nitrobenzoic acid)
EphA2       ephrin type-A receptor 2
FBS        fetal bovine serum
FCS        fluorescence correlation spectroscopy
FPGS       folypolyglutamyl synthetase
FR         folate receptor
FRET       fluorescence resonance energy transfer
HA2        hemagglutinin subunit 2
HBG        20 mM HEPES buffered 5% glucose pH 7.4
HCC        hepatocellular carcinoma
HOBt       1-hydroxy-benzotriazole
i.t.       intratumorally
i.v.       intravenously
KRAS-G12D   Kirsten rat sarcoma viral oncogene homolog G12D mutation
LMW        low molecular weight
LDER        local drug eluter
LNP        lipid nanoparticle
MPS        mononuclear phagocyte system
mRNA       messenger RNA
MTT        3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
MTX        methotrexate
N/P        pronatable amines of the oligomer/phosphates of the siRNA
NIR        near infrared
NMP        N-methyl-2-pyrrolidone
PAMAM       polyamidoamine
PEI         polyethylenimine
PLK1        polo-like kinase 1
PEG         polyethylene glycol
poly(I:C)   polyinosinic–polycytidylic acid
PRR         pattern recognition receptors
PTA         phosphotungstic acid
PyBOP       benzotriazol-1-yl-oxy-tris-pyrrolidino-phosphonium hexafluorophosphate
qRT-PCR     quantitative real-time polymerase chain reaction
RFC        reduced folate carrier
RISC       RNA-Induced Silencing Complex
RLU        relative light unit
ROS        reactive oxygen species
RNAi       RNA interference
RNS        reactive nitrogen species
<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>s.c.</td>
<td>subcutaneously</td>
</tr>
<tr>
<td>siRNA</td>
<td>small interfering RNA</td>
</tr>
<tr>
<td>Sph</td>
<td>succinoyl-pentaethylene hexamine</td>
</tr>
<tr>
<td>Stp</td>
<td>succinoyl-tetraethylene pentamine</td>
</tr>
<tr>
<td>TCEP</td>
<td>tris(2-carboxyethyl)phosphine</td>
</tr>
<tr>
<td>TEM</td>
<td>transmission electron microscopy</td>
</tr>
<tr>
<td>TIS</td>
<td>trisopropylsilane</td>
</tr>
<tr>
<td>TCP</td>
<td>targeted combinatorial polyplex</td>
</tr>
<tr>
<td>TFA</td>
<td>trifluoroacetic acid</td>
</tr>
<tr>
<td>TLP</td>
<td>targeted lipopolyplex</td>
</tr>
<tr>
<td>TLR</td>
<td>toll-like receptor</td>
</tr>
</tbody>
</table>
7 References


[120] K. Park, To PEGylate or not to PEGylate, that is not the question, J Control Release, 142 (2010) 147-148.
8 Publications

8.1 Original articles


8.2 Book chapter

Dian-Jang Lee, Taavi Lehto, Ernst Wagner. Sequence-defined oligoaminoamides for the delivery of siRNAs, Methods Mol Biol. 2015;1206:15-27

8.3 Submitted manuscript


8.4 Oral presentations


8.5 Poster presentations

1. Philipp M. Klein, Sören Reinhard, Dian-Jang Lee, Katharina Müller, Daniela Ponader, Laura Hartmann, Ernst Wagner. Precise integration of redox-sensitive cleavage sites for enhanced gene silencing and reduced toxicity of siRNA lipo-polypexes. 22th German Society for Gene Therapy (DG-GT) Annual Meeting, Sep 14-16, 2016, Heidelberg, Germany


8.6 Honors

2016  Best Manuscript of the Year in Physical Pharmacy and Biopharmaceutics section (PPB), American Association of Pharmaceutical Scientists (AAPS)

2016  Jan Feijen Poster Prize certified by J Control Release, 14th European Symposium on Controlled Drug Delivery (ESCDD)

2016  German Research Foundation (DFG) Clusters of Excellence Nanosystems Initiative Munich (NIM) Research Visit Grant

2015-2016  Elected Student Representative, Center for NanoScience (CeNS), Ludwig-Maximilians-Universität München

2015  European Molecular Biology Organization (EMBO) Short-Term Fellowship

2015  Center for NanoScience (CeNS) Travel Award, Ludwig-Maximilians-Universität München

2013-2016  Bavarian Research Foundation (BFS) Research Fellowship, Germany
Acknowledgements

As a veterinary student, I finally took part in an actual clinic in a neat scrub suit, learning to be a professional veterinarian after all these years of training and waiting. I am fascinated by the effects and kinetics of drugs, which appeared to have the possibility of instant gratification from an act of therapeutic intervention, a clear separation of before and after, of then and now, of suffering and cure. And also, it arouses my motivation in pursuing advanced graduate training in pharmaceutical science.

My research experience in Germany dramatically broadens my horizons. First of all, I appreciate the supervision from Prof. Dr. Ernst Wagner, who is a very dedicated and energetic scientist with sharp precision. I will never forget the moments while we chattered along the way to Kühfla in his BMW M3 at >200 km/h, while we discussed about how combinatorial polyplexes form hypothetic nanogel structures, and while we won the poster prize at ESCDD meeting. Prof. Dr. Joachim O. Rädler as my NIM co-advisor, and Prof. Dr. Don C. Lamb are always supportive to my studies. In AK Rädler, I learned a lot from the productive discussions with physicists and TEM measurements with Susi. In AK Lamb, it was a successful collaboration with Lena to characterize nanoplexes using FCS and she especially prepared a cake to celebrate the publication of this MTX paper.

I appreciate such great guidance from my colleagues to help me get involved in this environment while I was a newcomer. Taavi supervised my initial projects, and together we had a lot of fun in D 3.017. Andi gave me gene safety instruction, and Miriam gave me cell culture instruction fitting AK Wagner. Katharina, Adam and Petra taught me a lot of in vitro assays, and their working efficiency really impressed me. Uli is the most experienced scientist with our oligomer systems beside Prof. Wagner in the lab, he is very insightful about my experiments and provides significant inputs in MTX and TCP projects. Xiaowen invited Dongsheng and me to his place for a welcome dinner. Annika taught me in vivo assays and put a lot of efforts in application of our animal experiment permission. Moreover, “Scholz, C. & Wagner, E. (2012) Therapeutic plasmid DNA versus siRNA delivery: common and different tasks for synthetic carriers” was an excellent guide for me at that time, and till now, it is still classic.

I have learned not to be afraid of the setbacks but to learn from the setbacks; I have learned to savor every small victory, every subtle moment of ongoing experiments in the lab. During my PhD years, Dongsheng has been striving with me to develop TCP formulations for 2.5 years. Together with Philipp K. and Sören, we also screened many oligomers in different cell lines. Eva is very skillful at in vivo studies but sometimes too busy to have lunch. In the animal room, we performed experiments also on weekends, we monitored clinical signs of mice, and we shared the disappointments and excitements about in vivo studies. In addition, discussions with Wei and Jonathan are definitely valuable to me.

Meanwhile, I would like to thank our powerful support team: Wolfgang (chemicals, instruments, IT…difficult to list them all), Markus (animal facility maintenance), Olga (secretarial assistance), Melinda (mycoplasma tests), Ursula and Anna (cell culture room maintenance). Through numerous lab events organized by colleagues, we had glittering memories together: ski trips, BBQ, Oktoberfest (it is noteworthy that drunken Dongsheng vomited in Oktoberfest 2013) and gifts for PhD graduates (mainly by Ruth, Katharina, Ines and Jasmin), hiking, Fasching and Christmas parties (by Martina), celebrations for new publications (I still kept the wine bottles as souvenirs) (by Prof. Wagner and Uli), football games (by Andi and Bojan), and lab dinners (Philipp K. is a big fan of Peking duck) (by Wei and Jonathan).
Acknowledgements

I feel privileged that Prof. Ming-Thau Sheu (Taipei Medical University, Taiwan) always supports me without restrictions. He co-advised TLP and intratumoral pharmacokinetics projects, and visited AK Wagner in 2014. His senior PhD student, Yen-Chen, also had a research visit for this collaboration in Munich in the same year.

At systemic level, the fact that tumor vascular supply may limit tumor drug uptake is surely one of my major concerns. Apart from that, I am also interested in morphology and intracellular pharmacokinetics of siRNA polyplexes at ultrastructural or molecular level. Using TEM with Susi (AK Rädler), and using AFM with Dr. Rong Zhu (AK Hinterdorfer, Johannes-Kepler-Universität Linz, Austria), eventually I was able to see “these siRNA polyplexes which I have been working on for so long?” Furthermore, using immuno-TEM with Dr. Kärt Padari (AK Pooga, University of Tartu, Estonia), and using time-lapse CLSM and FRET study with Dr. Xueying Liu and Naoto (AK Kataoka, iCONM and University of Tokyo, Japan), I could even visualize how siRNA polyplexes interacted with receptors and trafficked through the endolysosomal pathway. Interestingly, it reminds me that while I was a sophomore in Prof. Ling-Ling Que’s class, she told us how delighted she was while she observed her research subject, Salmonella Typhimurium, under TEM, as a graduate student (in 1979). “It is just like...after expecting for months, for the first time you finally see your own baby!” So vividly, she said with full of joy. I couldn’t understand her at that time, but now I really feel the similar sense of achievement. Almost 4 decades later, thanks to more advanced technology, I not only see “my baby”, in this sense, but also see “my baby crawling and playing toys”.

An essential aspect of CeNS is a broad array of research activities at the nanoscale that seek to develop next-generation devices, therapeutics or techniques. I’m glad to be elected as student representative together with Franzi and Luisa, and planned many events to facilitate interactions among colleagues with diverse expertise/from different faculties. With Susanne’s indispensable help, we invited foreign speaker, and organized lab tour, BBQ, “Science in a Nutshell”/welcome party, and company visit.

Absolutely, it is my great honor to work with these talented colleagues, together we showed strong teamwork (also at interdisciplinary and international level), and encouragingly, our work has been recognized by representative journals and societies.

As John Donne said, “no man is an island.” For these years living in Germany, I especially thank Yen-Chi, Cheng-Chang, Pang-Yen and Ching-Ning. I really cherish the time spending with them and warm supports from them. Without their presences, my daily life in Munich can be lonely and tasteless (or even miserable). I also enjoy lunch time with Yu-Kai, Chien-Sin, Tsai-Hsuan, Fang-Yu, Hung-En, Hsin-Yi and Liang-Yu on Wednesdays, and basketball games with Peng, Philipp K., Sören, Philipp H. and Stephan (it is an advantage that basketball courts are always available because it is not a popular sport here).

I sincerely thank my beloved parents for that I was born physiologically healthy, which is so essential for one’s lifetime (though I am sure they never expected their son would guide them to visit Europe 29 years later). I appreciate that they carefully raised me up and cultivated me. I still remember my handwriting was strictly corrected by my father while I was in elementary school. My life philosophy (if anything positive) is deeply influenced by my mother. My lovely grandmother always worries about my diet and personal safety abroad. Also, I thank my younger brothers Wei-Ping and Wei-Jen for taking care of familial obligations for me in Taiwan. Wei-Jen as an IT engineer, particularly helped me to estimate the pharmacokinetic parameters using C program. Moreover, I often receive kind supports from other family members (uncles, aunts and cousins).
Finally, I have learned to appreciate the fact that although I don’t directly provide medical care for animals, my impact on animals and human beings through pharmaceutical research can be no less daunting and no less gratifying. Not only have I learned valuable knowledge and skills from these experiences, I realized how rewarding and meaningful a career for a pharmaceutical scientist can be. More importantly, I am clear that this is the type of career I seek.

I have learned so much, but I still have so much to learn.